VIOLIN Logo
VIOLIN Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
Virugen
Vaxjo
Vaxvec
Vaccine Mechanisms
Vaxism
Vaxar
Vaccine Literature
Litesearch
Vaxpresso
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
VIOLIN Wiki
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Documents
FAQs
Links
Acknowledgements
Contact Us
UMMS Logo

VIOLIN Curated References

Actinobacillus pleuropneumoniae

  1. Chiers et al., 1998: Chiers K, van Overbeke I, De Laender P, Ducatelle R, Carel S, Haesebrouck F. Effects of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the Apx toxins. The Veterinary quarterly. 1998; 20(2); 65-69. [PubMed: 9563163].
  2. Van et al., 2001: Van Overbeke I, Chiers K, Ducatelle R, Haesebrouck F. Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins. Journal of veterinary medicine. B, Infectious diseases and veterinary public health. 2001; 48(1); 15-20. [PubMed: 11254095].

Babesia bovis

  1. de and Combrink, 2006: de Waal DT, Combrink MP. Live vaccines against bovine babesiosis. Veterinary parasitology. 2006; 138(1-2); 88-96. [PubMed: 16504404].

Babesia canis

  1. Moreau et al., 1989: Moreau Y, Vidor E, Bissuel G, Dubreuil N. Vaccination against canine babesiosis: an overview of field observations. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1989; 83 Suppl; 95-96. [PubMed: 2623757].

Bacillus anthracis

  1. Bielinska et al., 2007: Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR Jr. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infection and immunity. 2007; 75(8); 4020-4029. [PubMed: 17502384].
  2. Brey, 2005: Brey RN. Molecular basis for improved anthrax vaccines. Advanced drug delivery reviews. 2005 Jun 17; 57(9); 1266-92. [PubMed: 15935874].
  3. CDC, 2000: Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) [http://www.cdc.gov/mmwr/PDF/rr/rr4915.pdf]
  4. Chabot et al., 2004: Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM. Anthrax capsule vaccine protects against experimental infection. Vaccine. 2004 Nov 15; 23(1); 43-7. [PubMed: 15519706].
  5. Chekanov et al., 2006: Chekanov AV, Remacle AG, Golubkov VS, Akatov VS, Sikora S, Savinov AY, Fugere M, Day R, Rozanov DV, Strongin AY. Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency. Archives of biochemistry and biophysics. 2006 Feb 1; 446(1); 52-9. [PubMed: 16384550].
  6. Coeshott et al., 2004: Coeshott CM, Smithson SL, Verderber E, Samaniego A, Blonder JM, Rosenthal GJ, Westerink MA. Pluronic F127-based systemic vaccine delivery systems. Vaccine. 2004 Jun 23; 22(19); 2396-405. [PubMed: 15193401].
  7. Coker et al., 2003: Coker PR, Smith KL, Fellows PF, Rybachuck G, Kousoulas KG, Hugh-Jones ME. Bacillus anthracis virulence in Guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonality. Journal of clinical microbiology. 2003 Mar; 41(3); 1212-8. [PubMed: 12624053].
  8. Cui et al., 2006: Cui Z, Sloat BR. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid. International journal of pharmaceutics. 2006 Jul 24; 317(2); 187-91. [PubMed: 16730934 ].
  9. FDA: Anthrax Vaccine Adsorbed: FDA: Anthrax Vaccine Adsorbed for Bacillus anthracis [http://www.fda.gov/cber/label/biopava0131022LB.pdf]
  10. Flick-Smith et al., 2002: Flick-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, Miller J, Titball RW, Williamson ED. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infection and immunity. 2002 Mar; 70(3); 1653-6. [PubMed: 11854261].
  11. Galloway et al., 2004: Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, Estep J. Genetic immunization against anthrax. Vaccine. 2004 Apr 16; 22(13-14); 1604-8. [PubMed: 15068841].
  12. Glomski et al., 2007: Glomski IJ, Corre JP, Mock M, Goossens PL. Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. Journal of immunology (Baltimore, Md. : 1950). 2007 Mar 1; 178(5); 2646-50. [PubMed: 17312104 ].
  13. Gu et al., 1999: Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine. 1999 Jan 28; 17(4); 340-4. [PubMed: 9987172].
  14. Hahn et al., 2004: Hahn UK, Alex M, Czerny CP, Bohm R, Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. International journal of medical microbiology : IJMM. 2004 Jul; 294(1); 35-44. [PubMed: 15293452].
  15. Hanna et al., 1999: Hanna PC, Ireland JA. Understanding Bacillus anthracis pathogenesis. Trends in microbiology. 1999 May; 7(5); 180-2. [PubMed: 10383221].
  16. Hermanson et al., 2004: Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proceedings of the National Academy of Sciences of the United States of America. 2004 Sep 14; 101(37); 13601-6. [PubMed: 15342913].
  17. Hirsh et al, 2004: Hirsh DC, Biberstrein EL.. Bacillus. . 170-174.. Veterinary Microbiology, 2nd Ed.. 2004. Blackwell Publishing, Ames, Iowa...
  18. Klaschik et al., 2007: Klaschik S, Gursel I, Klinman DM. CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis. Molecular immunology. 2007 Feb; 44(6); 1095-104. [PubMed: 16930709].
  19. Klinman et al., 2004: Klinman DM, Xie H, Little SF, Currie D, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine. 2004 Jul 29; 22(21-22); 2881-6. [PubMed: 15246624 ].
  20. Kutsenko et al., 2002: Kutsenko AS, Gizatullin RZ, Al-Amin AN, Wang F, Kvasha SM, Podowski RM, Matushkin YG, Gyanchandani A, Muravenko OV, Levitsky VG, Kolchanov NA, Protopopov AI, Kashuba VI, Kisselev LL, Wasserman W, Wahlestedt C, Zabarovsky ER. NotI flanking sequences: a tool for gene discovery and verification of the human genome. Nucleic acids research. 2002 Jul 15; 30(14); 3163-70. [PubMed: 12136098].
  21. Leppla et al., 2002: Leppla SH, Robbins JB, Schneerson R, Shiloach J. Development of an improved vaccine for anthrax. The Journal of clinical investigation. 2002 Jul; 110(2); 141-4. [PubMed: 12122102].
  22. Little et al., 1986: Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infection and immunity. 1986 May; 52(2); 509-12. [PubMed: 3084385].
  23. PathPort: Virginia Bioinformatics Institute [http://pathport.vbi.vt.edu/pathinfo/pathogens/Bacillus-anthracis_Info.shtml]
  24. Pittman et al., 2006: Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine. 2006 Apr 24; 24(17); 3654-60. [PubMed: 16497418].
  25. Price et al., 2001: Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infection and immunity. 2001 Jul; 69(7); 4509-15. [PubMed: 11401993].
  26. Rhie et al., 2003: Rhie GE, Roehrl MH, Mourez M, Collier RJ, Mekalanos JJ, Wang JY. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proceedings of the National Academy of Sciences of the United States of America. 2003 Sep 16; 100(19); 10925-30. [PubMed: 12960361].
  27. Ribot et al., 2006: Ribot WJ, Powell BS, Ivins BE, Little SF, Johnson WM, Hoover TA, Norris SL, Adamovicz JJ, Friedlander AM, Andrews GP. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine. 2006 Apr 24; 24(17); 3469-76. [PubMed: 16519970].
  28. Schneerson et al., 2003: Schneerson R, Kubler-Kielb J, Liu TY, Dai ZD, Leppla SH, Yergey A, Backlund P, Shiloach J, Majadly F, Robbins JB. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proceedings of the National Academy of Sciences of the United States of America. 2003 Jul 22; 100(15); 8945-50. [PubMed: 12857944].
  29. Smith et al., 2006: Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology. 2006 Sep 30; 353(2); 344-56. [PubMed: 16820183].
  30. Spore vaccine: Anthrax Spore Vaccine [http://www.atozvetsupply.com/Anthrax-Vaccine-p/313-csav.htm]
  31. Wang et al., 2004: Wang TT, Fellows PF, Leighton TJ, Lucas AH. Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS immunology and medical microbiology. 2004 Apr 9; 40(3); 231-7. [PubMed: 15039099].
  32. Xie et al., 2005: Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, Klinman DM. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infection and immunity. 2005 Feb; 73(2); 828-33. [PubMed: 15664922].

Bordetella avium

  1. Jackwood and Saif, 1985: Jackwood MW, Saif YM. Efficacy of a commercial turkey coryza vaccine (Art-Vax) in turkey poults. Avian diseases. 1985; 29(4); 1130-1139. [PubMed: 3833219].

Bovine herpesvirus 1

  1. van et al., 1996: van Oirschot JT, Kaashoek MJ, Rijsewijk FA. Advances in the development and evaluation of bovine herpesvirus 1 vaccines. Veterinary microbiology. 1996; 53(1-2); 43-54. [PubMed: 9010997].

Brucella spp.

  1. Adone et al., 2005: Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G, Pasquali P. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infection and immunity. 2005; 73(7); 4198-4204. [PubMed: 15972510].
  2. Al-Mariri et al., 2001: Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, Walravens K, Letesson JJ. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infection and immunity. 2001 Aug; 69(8); 4816-22. [PubMed: 11447155 ].
  3. Arenas-Gamboa et al., 2008: Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. Immunization with a Single Dose of a Microencapsulated Brucella melitensis Mutant Enhances Protection Against Wild-type Challenge. Infection and immunity. 2008; ; . [PubMed: 18362129].
  4. Arenas-Gamboa et al., 2009: Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Wong-Gonzalez A, Rice-Ficht AC. Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres. Journal of wildlife diseases. 2009; 45(1); 165-173. [PubMed: 19204345].
  5. Banai, 2002: Banai M. Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: laboratory aspects and field observations. Veterinary microbiology. 2002 Dec 20; 90(1-4); 497-519. [PubMed: 12414167].
  6. Bhattacharjee et al., 2002: Bhattacharjee AK, Van de Verg L, Izadjoo MJ, Yuan L, Hadfield TL, Zollinger WD, Hoover DL. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein. Infection and immunity. 2002; 70(7); 3324-3329. [PubMed: 12065469].
  7. Bhattacharjee et al., 2006: Bhattacharjee AK, Izadjoo MJ, Zollinger WD, Nikolich MP, Hoover DL. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine. Infection and immunity. 2006 Oct; 74(10); 5820-5. [PubMed: 16988260].
  8. Blasco et al., 1993: Blasco JM, Gamazo C, Winter AJ, Jimenez de Bagues MP, Marin C, Barberan M, Moriyon I, Alonso-Urmeneta B, Diaz R. Evaluation of whole cell and subcellular vaccines against Brucella abortus in rams. Veterinary immunology and immunopathology. 1993 Aug; 37(3-4); 257-70. [PubMed: 8236802].
  9. Bosseray, 1991: Bosseray N. Brucella melitensis Rev. 1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice. Biologicals : journal of the International Association of Biological Standardization. 1991 Oct; 19(4); 355-63. [PubMed: 1797046].
  10. Cassataro et al., 2004: Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA, Baldi PC. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clinical and diagnostic laboratory immunology. 2004 Jan; 11(1); 111-4. [PubMed: 14715555].
  11. Cassataro et al., 2005: Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, Bowden R, Pasquevich KA, Fossati CA, Giambartolomei GH. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infection and immunity. 2005 Oct; 73(10); 6537-46. [PubMed: 16177328].
  12. Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A DNA vaccine coding for the quimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine. 2007 Jun 12; ; . [PubMed: 17600596].
  13. Cassataro et al., 2007: Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH, Goldbaum FA. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine. 2007 May 30; 25(22); 4437-46. [PubMed: 17442465].
  14. Cassataro et al., 2007: Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la Barrera S, Bowden R, Fossati CA, Giambartolomei GH. Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clinical and vaccine immunology : CVI. 2007; 14(7); 869-874. [PubMed: 17428946].
  15. Cheville, 2000: Cheville NF. Development, testing and commercialization of a new brucellosis vaccine for cattle. Annals of the New York Academy of Sciences. 2000; 916; 147-53. [PubMed: 11193615].
  16. Cloeckaert et al., 2002: Cloeckaert A, Grayon M, Grepinet O. Identification of Brucella melitensis vaccine strain Rev.1 by PCR-RFLP based on a mutation in the rpsL gene. Vaccine. 2002 Jun 7; 20(19-20); 2546-50. [PubMed: 12057611].
  17. Colby et al., 2002: Colby LA, Schurig GG, Elzer PH. An indirect ELISA to detect the serologic response of elk (Cervus elaphus nelsoni) inoculated with Brucella abortus strain RB51. Journal of wildlife diseases. 2002; 38(4); 752-759. [PubMed: 12528442].
  18. Commander et al., 2007: Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine. 2007; 25(1); 43-54. [PubMed: 17049676].
  19. Cook et al., 2001: Cook WE, Williams ES, Thorne ET, Taylor SK, Anderson S. Safety of Brucella abortus strain RB51 in deer mice. Journal of wildlife diseases. 2001; 37(3); 621-625. [PubMed: 11504238].
  20. Corbel, 1997: Corbel MJ. Recent advances in brucellosis. Journal of medical microbiology. 1997 Feb; 46(2); 101-3. [PubMed: 9060868 ].
  21. Delpino et al., 2007a: Delpino MV, Estein SM, Fossati CA, Baldi PC. Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria. Clinical and vaccine immunology : CVI. 2007; 14(10); 1296-1301. [PubMed: 17715332].
  22. Delpino et al., 2007b: Delpino MV, Estein SM, Fossati CA, Baldi PC, Cassataro J. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine. 2007; 25(37-38); 6721-6729. [PubMed: 17686554].
  23. Drazek et al., 1995: Drazek ES, Houng HS, Crawford RM, Hadfield TL, Hoover DL, Warren RL. Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages. Infection and immunity. 1995; 63(9); 3297-3301. [PubMed: 7642258].
  24. ELBERG and FAUNCE, 1957: ELBERG SS, FAUNCE K Jr. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. Journal of bacteriology. 1957; 73(2); 211-217. [PubMed: 13416171].
  25. Estein et al., 2003: Estein SM, Cassataro J, Vizcaino N, Zygmunt MS, Cloeckaert A, Bowden RA. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella abortus infection in BALB/c mice. Microbes and infection / Institut Pasteur. 2003 Feb; 5(2); 85-93. [PubMed: 12650766].
  26. Estevan et al., 2006: Estevan M, Gamazo C, Grilló MJ, Del Barrio GG, Blasco JM, Irache JM. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine. 2006; 24(19); 4179-4187. [PubMed: 16481077].
  27. Fernandes et al., 1996: Fernandes DM, Jiang X, Jung JH, Baldwin CL. Comparison of T cell cytokines in resistant and susceptible mice infected with virulent Brucella abortus strain 2308. FEMS immunology and medical microbiology. 1996 Dec 31; 16(3-4); 193-203. [PubMed: 9116636 ].
  28. Gee et al., 2005: Gee JM, Valderas MW, Kovach ME, Grippe VK, Robertson GT, Ng WL, Richardson JM, Winkler ME, Roop RM 2nd. The Brucella abortus Cu,Zn superoxide dismutase is required for optimal resistance to oxidative killing by murine macrophages and wild-type virulence in experimentally infected mice. Infection and immunity. 2005 May; 73(5); 2873-80. [PubMed: 15845493].
  29. Geong et al., 2000: Geong M, Robertson ID. Response of Bali cattle (Bos javanicus) to vaccination with Brucella abortus strain 19 in West Timor. Preventive veterinary medicine. 2000 Nov 16; 47(3); 177-86. [PubMed: 11058778].
  30. Goldbaum et al., 1999: Goldbaum FA, Velikovsky CA, Baldi PC, Mortl S, Bacher A, Fossati CA. The 18-kDa cytoplasmic protein of Brucella species --an antigen useful for diagnosis--is a lumazine synthase. Journal of medical microbiology. 1999 Sep; 48(9); 833-9. [PubMed: 10482294 ].
  31. Guilloteau et al., 2006: Guilloteau LA, Laroucau K, Olivier M, Grillo MJ, Marin CM, Verger JM, Blasco JM. Residual virulence and immunogenicity of CGV26 and CGV2631 B. melitensis Rev. 1 deletion mutant strains in sheep after subcutaneous or conjunctival vaccination. Vaccine. 2006; 24(17); 3461-3468. [PubMed: 16519974].
  32. Gupta et al., 2007: Gupta VK, Rout PK, Vihan VS. Induction of immune response in mice with a DNA vaccine encoding outer membrane protein (omp31) of Brucella melitensis 16M. Research in veterinary science. 2007; 82(3); 305-313. [PubMed: 17014873].
  33. Hamdy et al., 2002: Hamdy ME, El-Gibaly SM, Montasser AM. Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3. Veterinary microbiology. 2002; 88(1); 85-94. [PubMed: 12119140].
  34. He et al., 2001: He Y, Vemulapalli R, Zeytun A, Schurig GG. Induction of specific cytotoxic lymphocytes in mice vaccinated with Brucella abortus RB51. Infection and immunity. 2001 Sep; 69(9); 5502-8. [PubMed: 11500423 ].
  35. He et al., 2002: He Y, Vemulapalli R, Schurig GG. Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type. Infection and immunity. 2002 May; 70(5); 2535-43. [PubMed: 11953393].
  36. Hemmen et al., 1995: Hemmen F, Weynants V, Scarcez T, Letesson JJ, Saman E. Cloning and sequence analysis of a newly identified Brucella abortus gene and serological evaluation of the 17-kilodalton antigen that it encodes. Clinical and diagnostic laboratory immunology. 1995 May; 2(3); 263-7. [PubMed: 7664168 ].
  37. High et al., 2007: High KP, Prasad R, Marion CR, Schurig GG, Boyle SM, Sriranganathan N. Outcome and immune responses after Brucella abortus infection in young adult and aged mice. Biogerontology. 2007; 8(5); 583-593. [PubMed: 17653832].
  38. Hoover et al., 1999: Hoover DL, Crawford RM, Van De Verg LL, Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Warren RL, Nikolich MP, Hadfield TL. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK). Infection and immunity. 1999; 67(11); 5877-5884. [PubMed: 10531243].
  39. Izadjoo et al., 2004: Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M. Infection and immunity. 2004; 72(7); 4031-4039. [PubMed: 15213148].
  40. Jacques et al., 2007: Jacques I, Verger JM, Laroucau K, Grayon M, Vizcaino N, Peix A, Cortade F, Carreras F, Guilloteau LA. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep. Vaccine. 2007 Jan 15; 25(5); 794-805. [PubMed: 17070627].
  41. Januszewski et al., 2001: Januszewski MC, Olsen SC, McLean RG, Clark L, Rhyan JC. Experimental infection of nontarget species of rodents and birds with Brucella abortus strain RB51 vaccine. Journal of wildlife diseases. 2001; 37(3); 532-537. [PubMed: 11504226].
  42. Jensen and Halling, 2008: Jensen AE, Halling SM. Effect of polymyxin B and environmental conditions on isolation of Brucella species and the vaccine strain RB51. Comparative immunology, microbiology and infectious diseases. 2008; ; . [PubMed: 18814911].
  43. Jiménez et al., 1994: Jiménez de Bagüés MP, Elzer PH, Jones SM, Blasco JM, Enright FM, Schurig GG, Winter AJ. Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella abortus. Infection and immunity. 1994; 62(11); 4990-4996. [PubMed: 7927779].
  44. Kahl-McDonagh and Ficht, 2006: Kahl-McDonagh MM, Ficht TA. Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infection and immunity. 2006; 74(7); 4048-4057. [PubMed: 16790778].
  45. Kahl-McDonagh et al., 2007: Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infection and immunity. 2007; 75(10); 4923-4932. [PubMed: 17664263].
  46. Ko et al., 2002: Ko J, Gendron-Fitzpatrick A, Ficht TA, Splitter GA. Virulence criteria for Brucella abortus strains as determined by interferon regulatory factor 1-deficient mice. Infection and immunity. 2002; 70(12); 7004-7012. [PubMed: 12438380].
  47. Kohler et al., 2002: Kohler S, Foulongne V, Ouahrani-Bettache S, Bourg G, Teyssier J, Ramuz M, Liautard JP. The analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell. Proceedings of the National Academy of Sciences of the United States of America. 2002 Nov 26; 99(24); 15711-6. [PubMed: 12438693 ].
  48. Laplagne et al., 2004: Laplagne DA, Zylberman V, Ainciart N, Steward MW, Sciutto E, Fossati CA, Goldbaum FA. Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides. Proteins. 2004 Dec 1; 57(4); 820-8. [PubMed: 15390265].
  49. Lee et al., 1999: Lee IK, Olsen SC, Kehrli M, Bolin CA. The adjuvant effect of a single dose of interleukin-12 on murine immune responses to live or killed Brucella abortus strain RB51. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 1999; 63(4); 284-287. [PubMed: 10534009].
  50. Lee et al., 2001: Lee IK, Olsen SC, Bolin CA. Effects of exogenous recombinant interleukin-12 on immune responses and protection against Brucella abortus in a murine model. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2001; 65(4); 223-228. [PubMed: 11768128].
  51. Letesson et al., 1997: Letesson JJ, Tibor A, van Eynde G, Wansard V, Weynants V, Denoel P, Saman E. Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay. Clinical and diagnostic laboratory immunology. 1997 Sep; 4(5); 556-64. [PubMed: 9302205].
  52. Li, 1991: Li HZ. [A pathohistological study on experimental brucellosis in inbred mice]. Zhonghua bing li xue za zhi Chinese journal of pathology. 1991 Jun; 20(2); 134-6. [PubMed: 1914022 ].
  53. Longo et al., 2009: Longo M, Mallardo K, Montagnaro S, De Martino L, Gallo S, Fusco G, Galiero G, Guarino A, Pagnini U, Iovane G. Shedding of Brucella abortus rough mutant strain RB51 in milk of water buffalo (Bubalus bubalis). Preventive veterinary medicine. 2009; 90(1-2); 113-118. [PubMed: 19362381].
  54. Luo et al., 2006a: Luo DY, Li P, Xing L, Zhao GY, Shi W, Zhang SL, Wang XL. DNA vaccine encoding L7/L12-P39 of Brucella abortus induces protective immunity in BALB/c mice. Chinese medical journal. 2006 Feb 20; 119(4); 331-4. [PubMed: 16537031].
  55. Luo et al., 2006b: Luo D, Ni B, Li P, Shi W, Zhang S, Han Y, Mao L, He Y, Wu Y, Wang X. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infection and immunity. 2006; 74(5); 2734-2741. [PubMed: 16622210].
  56. Makar et al., 1975: Makar AB, McMartin KE, Palese M, Tephly TR. Formate assay in body fluids: application in methanol poisoning. Biochemical medicine. 1975; 13(2); 117-126. [PubMed: 1].
  57. Mallick et al., 2007: Mallick AI, Singha H, Khan S, Anwar T, Ansari MA, Khalid R, Chaudhuri P, Owais M. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis. Vaccine. 2007; 25(46); 7873-7884. [PubMed: 17931756].
  58. Martins et al., 2009: Martins H, Garin-Bastuji B, Lima F, Flor L, Pina Fonseca A, Boinas F. Eradication of bovine brucellosis in the Azores, Portugal-Outcome of a 5-year programme (2002-2007) based on test-and-slaughter and RB51 vaccination. Preventive veterinary medicine. 2009; 90(1-2); 80-89. [PubMed: 19439382].
  59. Montaraz et al., 1986: Montaraz JA, Winter AJ. Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice. Infection and immunity. 1986 Aug; 53(2); 245-51. [PubMed: 3089933 ].
  60. Moriyon et al., 2004: Moriyon I, Grillo MJ, Monreal D, Gonzalez D, Marin C, Lopez-Goni I, Mainar-Jaime RC, Moreno E, Blasco JM. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Veterinary research. 2004 Jan-Feb; 35(1); 1-38. [PubMed: 15099501].
  61. Munoz-Montesino et al., 2004: Munoz-Montesino C, Andrews E, Rivers R, Gonzalez-Smith A, Moraga-Cid G, Folch H, Cespedes S, Onate AA. Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infection and immunity. 2004 Apr; 72(4); 2081-7. [PubMed: 15039330].
  62. Nol et al., 2009: Nol P, Olsen SC, Rhyan JC. Experimental infection of Richardson's ground squirrels (Spermophilus richardsonii) with attenuated and virulent strains of Brucella abortus. Journal of wildlife diseases. 2009; 45(1); 189-195. [PubMed: 19204348].
  63. Oliveira et al., 1994: Oliveira SC, Zhu Y, Splitter G. Sequences of the rplJL operon containing the L10 and L7/L12 genes from Brucella abortus. Gene. 1994 Mar 11; 140(1); 137-8. [PubMed: 8125331 ].
  64. Oliveira et al., 1996: Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine. 1996 Jul; 14(10); 959-62. [PubMed: 8873388 ].
  65. Olsen et al., 2004: Olsen SC, Rhyan J, Gidlewski T, Goff J, Stoffregen WC. Safety of Brucella abortus strain RB51 in black bears. Journal of wildlife diseases. 2004; 40(3); 429-433. [PubMed: 15465709].
  66. Olsen et al., 2007: Olsen SC, Waters WR, Stoffregen WS. An aerosolized Brucella spp. challenge model for laboratory animals. Zoonoses and public health. 2007; 54(8); 281-285. [PubMed: 17894637].
  67. Olsen et al., 2009: Olsen SC, Boyle SM, Schurig GG, Sriranganathan NN. Immune responses and protection against experimental challenge after vaccination of bison with Brucella abortus strain RB51 or RB51 overexpressing superoxide dismutase and glycosyltransferase genes. Clinical and vaccine immunology : CVI. 2009; 16(4); 535-540. [PubMed: 19176693].
  68. Onate et al., 2003: Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, Folch H, Andrews E. A DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus induces protective immunity in BALB/c mice. Infection and immunity. 2003 Sep; 71(9); 4857-61. [PubMed: 12933826].
  69. Palmer et al., 1996: Palmer MV, Cheville NF, Tatum FM. Morphometric and histopathologic analysis of lymphoid depletion in murine spleens following infection with Brucella abortus strains 2308 or RB51 or an htrA deletion mutant. Veterinary pathology. 1996; 33(3); 282-289. [PubMed: 8740701].
  70. Parent et al., 2007: Parent MA, Goenka R, Murphy E, Levier K, Carreiro N, Golding B, Ferguson G, Roop RM 2nd, Walker GC, Baldwin CL. Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain. Microbes and infection / Institut Pasteur. 2007; 9(1); 55-62. [PubMed: 17196866].
  71. Pasquali et al., 2001: Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F. Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection. Infection and immunity. 2001; 69(10); 6541-6544. [PubMed: 11553603].
  72. Pasquali et al., 2003: Pasquali P, Rosanna A, Pistoia C, Petrucci P, Ciuchini F. Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. Infection and immunity. 2003; 71(5); 2326-2330. [PubMed: 12704101].
  73. Pasquevich et al., 2009: Pasquevich KA, Estein SM, García Samartino C, Zwerdling A, Coria LM, Barrionuevo P, Fossati CA, Giambartolomei GH, Cassataro J. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infection and immunity. 2009; 77(1); 436-445. [PubMed: 18981242].
  74. Poester et al., 2006: Poester FP, Gonçalves VS, Paixão TA, Santos RL, Olsen SC, Schurig GG, Lage AP. Efficacy of strain RB51 vaccine in heifers against experimental brucellosis. Vaccine. 2006; 24(25); 5327-5334. [PubMed: 16713034].
  75. Rajasekaran et al., 2008: Rajasekaran P, Seleem MN, Contreras A, Purwantini E, Schurig GG, Sriranganathan N, Boyle SM. Brucella abortus strain RB51 leucine auxotroph as an environmentally safe vaccine for plasmid maintenance and antigen overexpression. Applied and environmental microbiology. 2008; 74(22); 7051-7055. [PubMed: 18836016].
  76. Ramamoorthy et al., 2007: Ramamoorthy S, Sanakkayala N, Vemulapalli R, Duncan RB, Lindsay DS, Schurig GS, Boyle SM, Kasimanickam R, Sriranganathan N. Prevention of lethal experimental infection of C57BL/6 mice by vaccination with Brucella abortus strain RB51 expressing Neospora caninum antigens. International journal for parasitology. 2007; 37(13); 1521-1529. [PubMed: 17568587].
  77. Roop et al., 2004: Roop RM 2nd, Bellaire BH, Valderas MW, Cardelli JA. Adaptation of the Brucellae to their intracellular niche. Molecular microbiology. 2004 May; 52(3); 621-30. [PubMed: 15101970 ].
  78. Schurig et al., 1991: Schurig GG, Roop RM 2nd, Bagchi T, Boyle S, Buhrman D, Sriranganathan N. Biological properties of RB51; a stable rough strain of Brucella abortus. Veterinary microbiology. 1991 Jul; 28(2); 171-88. [PubMed: 1908158].
  79. Schurig et al., 2002: Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Veterinary microbiology. 2002 Dec 20; 90(1-4); 479-96. [PubMed: 12414166].
  80. Stevens et al., 1994a: Stevens MG, Olsen SC, Pugh GW Jr. Lymphocyte proliferation in response to Brucella abortus 2308 or RB51 antigens in mice infected with strain 2308, RB51, or 19. Infection and immunity. 1994; 62(10); 4659-4663. [PubMed: 7927736].
  81. Stevens et al., 1994b: Stevens MG, Olsen SC, Pugh GW Jr, Palmer MV. Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308. Infection and immunity. 1994 Aug; 62(8); 3206-12. [PubMed: 8039890].
  82. Stevens et al., 1995a: Stevens MG, Olsen SC, Pugh GW Jr. Comparison of spleen cell proliferation in response to Brucella abortus 2308 lipopolysaccharide or proteins in mice vaccinated with strain 19 or RB51. Infection and immunity. 1995; 63(8); 3199-3205. [PubMed: 7622248].
  83. Stevens et al., 1995b: Stevens MG, Olsen SC, Pugh GW Jr, Brees D. Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. Infection and immunity. 1995; 63(1); 264-270. [PubMed: 7806364].
  84. Stevens et al., 1996: Stevens MG, Olsen SC, Palmer MV, Pugh GW Jr. Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51. Infection and immunity. 1996; 64(11); 4534-4541. [PubMed: 8890203].
  85. Stoffregen et al., 2006: Stoffregen WC, Olsen SC, Bricker BJ. Parenteral vaccination of domestic pigs with Brucella abortus strain RB51. American journal of veterinary research. 2006; 67(10); 1802-1808. [PubMed: 17014337].
  86. Tibor et al., 1998: Tibor A, Jacques I, Guilloteau L, Verger JM, Grayon M, Wansard V, Letesson JJ. Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice. Infection and immunity. 1998; 66(11); 5561-5564. [PubMed: 9784574].
  87. Tobias et al., 1992: Tobias L, Schurig GG, Cordes DO. Comparative behaviour of Brucella abortus strains 19 and RB51 in the pregnant mouse. Research in veterinary science. 1992; 53(2); 179-183. [PubMed: 1439207].
  88. Velikovsky et al., 2002: Velikovsky CA, Cassataro J, Giambartolomei GH, Goldbaum FA, Estein S, Bowden RA, Bruno L, Fossati CA, Spitz M. A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB/c mice. Infection and immunity. 2002 May; 70(5); 2507-11. [PubMed: 11953389 ].
  89. Vemulapalli et al., 2000a: Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infection and immunity. 2000 Jun; 68(6); 3286-9. [PubMed: 10816475].
  90. Vemulapalli et al., 2000b: Vemulapalli R, He Y, Buccolo LS, Boyle SM, Sriranganathan N, Schurig GG. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation. Infection and immunity. 2000 Jul; 68(7); 3927-32. [PubMed: 10858205].
  91. Vemulapalli et al., 2004: Vemulapalli R, Contreras A, Sanakkayala N, Sriranganathan N, Boyle SM, Schurig GG. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice. Veterinary microbiology. 2004 Sep 8; 102(3-4); 237-45. [PubMed: 15327798].
  92. Winter et al., 1988: Winter AJ, Rowe GE, Duncan JR, Eis MJ, Widom J, Ganem B, Morein B. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infection and immunity. 1988; 56(11); 2808-2817. [PubMed: 2844673].
  93. Winter et al., 1996: Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, Elzer PH, Kopec JD. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. American journal of veterinary research. 1996 May; 57(5); 677-83. [PubMed: 8723881].
  94. Xin, 1986: Xin X. Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine. Vaccine. 1986; 4(4); 212-216. [PubMed: 3541425].
  95. Yang et al., 2006: Yang X, Becker T, Walters N, Pascual DW. Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge. Infection and immunity. 2006; 74(7); 3874-3879. [PubMed: 16790759].
  96. Yang et al., 2007: Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine. 2007; 25(12); 2261-2268. [PubMed: 17239499].
  97. Yu et al., 2007: Yu DH, Hu XD, Cai H. A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA and cell biology. 2007 Jun; 26(6); 435-43. [PubMed: 17570767].

Campylobacter jejuni

  1. Abimiku et al., 1989: Abimiku AG, Dolby JM, Borriello SP. Comparison of different vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse. Epidemiology and infection. 1989 Apr; 102(2); 271-80. [PubMed: 2703020 ].
  2. Abulreesh et al., 2006: Abulreesh HH, Paget TA, Goulder R. Campylobacter in waterfowl and aquatic environments: incidence and methods of detection. Environmental science & technology. 2006 Dec 1; 40(23); 7122-31. [PubMed: 17180958].
  3. Andrews, 1998: Andrews GP. The enteric Campylobacter: they are everywhere. Clinical laboratory science : journal of the American Society for Medical Technology. 1998 Sep-Oct; 11(5); 305-8. [PubMed: 10186956].
  4. Baqar et al., 1995a: Baqar S, Bourgeois AL, Schultheiss PJ, Walker RI, Rollins DM, Haberberger RL, Pavlovskis OR. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine. 1995 Jan; 13(1); 22-8. [PubMed: 7539199].
  5. Baqar et al., 1995b: Baqar S, Applebee LA, Bourgeois AL. Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice. Infection and immunity. 1995 Sep; 63(9); 3731-5. [PubMed: 7642317].
  6. Burr et al., 2005: Burr DH, Rollins D, Lee LH, Pattarini DL, Walz SS, Tian JH, Pace JL, Bourgeois AL, Walker RI. Prevention of disease in ferrets fed an inactivated whole cell Campylobacter jejuni vaccine. Vaccine. 2005 Jul 29; 23(34); 4315-21. [PubMed: 16005742 ].
  7. Dolby et al., 1986: Dolby JM, Newell DG. The protection of infant mice from colonization with Campylobacter jejuni by vaccination of the dams. The Journal of hygiene. 1986 Apr; 96(2); 143-51. [PubMed: 3701036 ].
  8. Engberg, 2006: Engberg J. Contributions to the epidemiology of Campylobacter infections. A review of clinical and microbiological studies. Danish medical bulletin. 2006 Nov; 53(4); 361-89. [PubMed: 17150145].
  9. Huang et al., 2007: Huang S, Sahin O, Zhang Q. Infection-induced antibodies against the major outer membrane protein of Campylobacter jejuni mainly recognize conformational epitopes. FEMS microbiology letters. 2007 Jul; 272(2); 137-43. [PubMed: 17521366].
  10. Jagusztyn-Krynicka et al., 2004: Jagusztyn-Krynicka EK, Wyszynska A, Raczko A. New approaches to development of mucosal vaccine against enteric bacterial pathogens; preventing campylobacteriosis. Polish journal of microbiology / Polskie Towarzystwo Mikrobiologow = The Polish Society of Microbiologists. 2004; 53 Suppl; 7-15. [PubMed: 15787191].
  11. Khoury et al., 1995: Khoury CA, Meinersmann RJ. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. Avian diseases. 1995 Oct-Dec; 39(4); 812-20. [PubMed: 8719215 ].
  12. Kopecko, 1997: Kopecko DJ. Regulatory considerations for Campylobacter vaccine development. The Journal of infectious diseases. 1997 Dec; 176 Suppl 2; S189-91. [PubMed: 9396709].
  13. Lee et al., 1999: Lee LH, Burg E 3rd, Baqar S, Bourgeois AL, Burr DH, Ewing CP, Trust TJ, Guerry P. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infection and immunity. 1999 Nov; 67(11); 5799-805. [PubMed: 10531231].
  14. Martin et al., 1999: Martin PR, Mulks MH. Cloning and characterization of a gene encoding an antigenic membrane protein from Actinobacillus pleuropneumoniae with homology to ABC transporters. FEMS immunology and medical microbiology. 1999 Aug 15; 25(3); 245-54. [PubMed: 10459579].
  15. Nelson et al., 2007: Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Apr 1; 44(7); 977-80. [PubMed: 17342653].
  16. Pawelec et al., 1997: Pawelec D, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Cloning and characterization of a Campylobacter jejuni 72Dz/92 gene encoding a 30 kDa immunopositive protein, component of the ABC transport system; expression of the gene in avirulent Salmonella typhimurium. FEMS immunology and medical microbiology. 1997 Oct; 19(2); 137-50. [PubMed: 9395059].
  17. Pawelec et al., 2000: Pawelec DP, Korsak D, Wyszynska AK, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Genetic diversity of the Campylobacter genes coding immunodominant proteins. FEMS microbiology letters. 2000 Apr 1; 185(1); 43-9. [PubMed: 10731605].
  18. Prokhorova et al., 2006: Prokhorova TA, Nielsen PN, Petersen J, Kofoed T, Crawford JS, Morsczeck C, Boysen A, Schrotz-King P. Novel surface polypeptides of Campylobacter jejuni as traveller's diarrhoea vaccine candidates discovered by proteomics. Vaccine. 2006 Sep 29; 24(40-41); 6446-55. [PubMed: 16824653].
  19. Rice et al., 1997: Rice BE, Rollins DM, Mallinson ET, Carr L, Joseph SW. Campylobacter jejuni in broiler chickens: colonization and humoral immunity following oral vaccination and experimental infection. Vaccine. 1997 Dec; 15(17-18); 1922-32. [PubMed: 9413103 ].
  20. Scott, 1997: Scott DA. Vaccines against Campylobacter jejuni. The Journal of infectious diseases. 1997 Dec; 176 Suppl 2; S183-8. [PubMed: 9396708].
  21. Sizemore et al., 2006: Sizemore DR, Warner B, Lawrence J, Jones A, Killeen KP. Live, attenuated Salmonella typhimurium vectoring Campylobacter antigens. Vaccine. 2006 May 1; 24(18); 3793-803. [PubMed: 16135393].
  22. Smibert, 1978: Smibert RM. The genus Campylobacter. Annual review of microbiology. 1978; 32; 673-709. [PubMed: 360978].
  23. Walker, 2005: Walker RI. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine. 2005 May 16; 23(26); 3369-85. [PubMed: 15837361].
  24. Wallis, 2004: Wallis TS. Vaccination against salmonella, enterohaemorrhagic E. coli and Campylobacter in food-producing animals. Developments in biologicals. 2004; 119; 343-50. [PubMed: 15742645].
  25. White et al., 1997: White PL, Baker AR, James WO. Strategies to control Salmonella and Campylobacter in raw poultry products. Revue scientifique et technique (International Office of Epizootics). 1997 Aug; 16(2); 525-41. [PubMed: 9501366].
  26. Wilkinson et al., 2003: Wilkinson J, Rood D, Minior D, Guillard K, Darre M, Silbart LK. Immune response to a mucosally administered aflatoxin B1 vaccine. Poultry science. 2003 Oct; 82(10); 1565-72. [PubMed: 14601734].
  27. Wyszynska et al., 2004: Wyszynska A, Raczko A, Lis M, Jagusztyn-Krynicka EK. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. Vaccine. 2004 Mar 29; 22(11-12); 1379-89. [PubMed: 15063560 ].

Cancer

  1. FDA: TICE BCG: FDA summary of approval for TICE BCG [http://www.fda.gov/Cber/sba/bcgorga082198S.pdf]

Canine coronavirus

  1. Pardo et al., 1999: Pardo MC, M. Mackowiak. Efficacy of a new canine-origin, modified-live virus vaccine against canine coronavirus. Canine Practice. 1999; 24; 6-8.

Chlamydophila abortus

  1. Chalmers et al., 1997: Chalmers WS, Simpson J, Lee SJ, Baxendale W. Use of a live chlamydial vaccine to prevent ovine enzootic abortion. The Veterinary record. 1997; 141(3); 63-67. [PubMed: 9257434].

Classical swine fever virus

  1. Moormann et al., 2000: Moormann RJ, Bouma A, Kramps JA, Terpstra C, De Smit HJ. Development of a classical swine fever subunit marker vaccine and companion diagnostic test. Veterinary microbiology. 2000; 73(2-3); 209-219. [PubMed: 10785329].
  2. van, 2003: van Aarle P. Suitability of an E2 subunit vaccine of classical swine fever in combination with the E(rns)-marker-test for eradication through vaccination. Developments in biologicals. 2003; 114; 193-200. [PubMed: 14677689].

Clostridium botulinum

  1. Arimitsu et al., 2004: Arimitsu H, Lee JC, Sakaguchi Y, Hayakawa Y, Hayashi M, Nakaura M, Takai H, Lin SN, Mukamoto M, Murphy T, Oguma K. Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins. Clinical and diagnostic laboratory immunology. 2004 May; 11(3); 496-502. [PubMed: 15138174].
  2. Arnon et al., 2001: Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA : the journal of the American Medical Association. 2001 Feb 28; 285(8); 1059-70. [PubMed: 11209178 ].
  3. Bennett et al., 2003: Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine. 2003 Jul 4; 21(23); 3110-7. [PubMed: 12804837 ].
  4. Boles et al., 2006: Boles J, West M, Montgomery V, Tammariello R, Pitt ML, Gibbs P, Smith L, LeClaire RD. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon : official journal of the International Society on Toxinology. 2006 Jun 15; 47(8); 877-84. [PubMed: 16730042 ].
  5. Byrne et al., 1998: Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infection and immunity. 1998 Oct; 66(10); 4817-22. [PubMed: 9746584].
  6. Byrne et al., 2000: Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie. 2000 Sep-Oct; 82(9-10); 955-66. [PubMed: 11086225].
  7. Jathoul et al., 2004: Jathoul AP, Holley JL, Garmory HS. Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine. 2004 Sep 28; 22(29-30); 3942-6. [PubMed: 15364442].
  8. Johnson, 1997: Johnson S. Antibody responses to clostridial infection in humans. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1997 Sep; 25 Suppl 2; S173-7. [PubMed: 9310668].
  9. Lee et al., 2006: Lee JS, Groebner JL, Hadjipanayis AG, Negley DL, Schmaljohn AL, Welkos SL, Smith LA, Smith JF. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine. 2006 Nov 17; 24(47-48); 6886-92. [PubMed: 16828936].
  10. Lohenry et al., 2006: Lohenry K, Foulke K. Botulism: rare, but deadly. JAAPA : official journal of the American Academy of Physician Assistants. 2006 Nov; 19(11); 41-5. [PubMed: 17124790 ].
  11. Martinez et al., 1999: Martinez R, Wobeser G. Immunization of ducks for type C botulism. Journal of wildlife diseases. 1999 Oct; 35(4); 710-5. [PubMed: 10574530 ].
  12. NCBI: Entrez Gene [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene]
  13. PathPort: Virginia Bioinformatics Institute [http://pathport.vbi.vt.edu/pathinfo/pathogens/Clostridium_botulinum_Info.shtml]
  14. Rubin et al., 1982: Rubin LG, Dezfulian M, Yolken RH. Serum antibody response to Clostridium botulinum toxin in infant botulism. Journal of clinical microbiology. 1982 Oct; 16(4); 770-1. [PubMed: 7153329].
  15. Siegel, 1988: Siegel LS. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. Journal of clinical microbiology. 1988 Nov; 26(11); 2351-6. [PubMed: 3235662].

Clostridium tetani

  1. Brook, 2008: Brook I. Current concepts in the management of Clostridium tetani infection. Expert review of anti-infective therapy. 2008; 6(3); 327-336. [PubMed: 18588497].
  2. FDA Boostrix: FDA Boostrix [http://www.fda.gov/cber/label/boostrixLB.pdf]
  3. FDA Decavac: FDA Decavac [http://www.fda.gov/cber/label/tdtadecavac120208LB.pdf]
  4. FDA Infanrix: FDA Infanrix [http://www.fda.gov/cber/products/infanrix.htm]
  5. FDA: Adacel: FDA: Adacel [http://www.fda.gov/cber/products/adacel.htm]
  6. FDA: DAPTACEL: FDA: DAPTACEL [http://www.fda.gov/cber/label/daptacelLB.pdf]
  7. FDA: dttadLB: FDA: Diphtheria and Tetanus Toxoids Adsorbed USP [http://www.fda.gov/cber/label/dttadLB.pdf]
  8. FDA: KINRIX: FDA: KINRIX [http://www.fda.gov/cber/label/kinrixLB.pdf]
  9. FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/cber/label/dtapgsk031607LB.pdf]
  10. FDA: Pentacel: FDA: Pentacel Vaccine [http://www.fda.gov/cber/label/pentacelLB.pdf]
  11. FDA: Tenivac: FDA: Tenivac [http://www.fda.gov/cber/products/tdtad.htm]
  12. FDA: Tetanus Toxoid Adsorbed by Sanofi Pasteur Inc: FDA: Tetanus Toxoid Adsorbed by Sanofi Pasteur Inc [http://www.fda.gov/Cber/label/ttoxave092305LB.pdf]
  13. FDA: Tripedia: FDA: Tripedia [http://www.fda.gov/cber/products/tripedia.htm]

Corynebacterium diphtheriae

  1. Adacel: Adacel [http://www.fda.gov/cber/label/adacelLB.pdf]
  2. Boostrix: Boostrix [http://www.fda.gov/cber/label/boostrixLB.pdf]
  3. CDC: Diphtheria: CDC: Diphtheria general information [http://www.cdc.gov/ncidod/dbmd/diseaseinfo/diptheria_t.htm]
  4. Decavac: Decavac [http://www.fda.gov/cber/label/tdtadecavac120208LB.pdf]
  5. FDA: DAPTACEL: FDA: DAPTACEL Vaccine [http://www.fda.gov/cber/label/daptacelLB.pdf]
  6. FDA: Diphtheria and Tetanus Toxoids Adsorbed USP: FDA: Diphtheria and Tetanus Toxoids Adsorbed USP [http://www.fda.gov/cber/label/dttadLB.pdf]
  7. FDA: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed: FDA: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed [http://www.fda.gov/cber/label/dtapave030701LB.pdf]
  8. FDA: INFANRIX: FDA: INFANRIX [http://www.fda.gov/cber/label/dtapgla070703LB.pdf]
  9. FDA: KINRIX: FDA: KINRIX Vaccine [http://www.fda.gov/cber/label/kinrixLB.pdf]
  10. FDA: Menactra: FDA: Menactra Vaccine [http://www.fda.gov/cber/label/menactraLB.pdf]
  11. FDA: Pediarix: FDA: Pediarix [http://www.fda.gov/cber/label/dtapgsk031607LB.pdf]
  12. FDA: Pentacel: FDA: Pentacel Vaccine [http://www.fda.gov/cber/label/pentacelLB.pdf]
  13. Tenivac: Tenivac [http://www.fda.gov/cber/label/tenivaclb.pdf]

Coxiella burnetii

  1. Ackland et al., 1994: Ackland JR, Worswick DA, Marmion BP. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990. The Medical journal of Australia. 1994; 160(11); 704-708. [PubMed: 8202006 ].
  2. Akporiaye and Baca, 1983: Akporiaye ET, Baca OG. Superoxide anion production and superoxide dismutase and catalase activities in Coxiella burnetii. Journal of bacteriology. 1983; 154(1); 520-523. [PubMed: 6300038 ].
  3. Arricau-Bouvery et al., 2005: Arricau-Bouvery N, Souriau A, Bodier C, Dufour P, Rousset E, Rodolakis A. Effect of vaccination with phase I and phase II Coxiella burnetii vaccines in pregnant goats. Vaccine. 2005; 23(35); 4392-4402. [PubMed: 16005747 ].
  4. Brennan et al., 2004: Brennan RE, Russell K, Zhang G, Samuel JE. Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections. Infection and immunity. 2004; 72(11); 6666-6675. [PubMed: 15501800].
  5. Burton et al., 1971: Burton PR, Kordova N, Paretsky D. Electron microscopic studies of the rickettsia Coxiella burneti: entry, lysosomal response, and fate of rickettsial DNA in L-cells. Canadian journal of microbiology. 1971; 17(2); 143-150. [PubMed: 4100953].
  6. Burton et al., 1978: Burton PR, Stueckemann J, Welsh RM, Paretsky D. Some ultrastructural effects of persistent infections by the rickettsia Coxiella burnetii in mouse L cells and green monkey kidney (Vero) cells. Infection and immunity. 1978; 21(2); 556-566. [PubMed: 99368].
  7. Capo et al., 1999: Capo C, Lindberg FP, Meconi S, Zaffran Y, Tardei G, Brown EJ, Raoult D, Mege JL. Subversion of monocyte functions by coxiella burnetii: impairment of the cross-talk between alphavbeta3 integrin and CR3. Journal of immunology (Baltimore, Md. : 1950). 1999; 163(11); 6078-6085. [PubMed: 10570297].
  8. Fries et al., 1993: Fries LF, Waag DM, Williams JC. Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever. Infection and immunity. 1993; 61(4); 1251-1258. [PubMed: 8454328 ].
  9. Hackstadt and Williams, 1981: Hackstadt T, Williams JC. Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii. Proceedings of the National Academy of Sciences of the United States of America. 1981; 78(5); 3240-3244. [PubMed: 6942430].
  10. Hackstadt et al., 1985: Hackstadt T, Peacock MG, Hitchcock PJ, Cole RL. Lipopolysaccharide variation in Coxiella burnetti: intrastrain heterogeneity in structure and antigenicity. Infection and immunity. 1985; 48(2); 359-365. [PubMed: 3988339 ].
  11. Johnson et al., 1977: Johnson JW, McLeod CG, Stookey JL, Higbee GA, Pedersen CE Jr. Lesions in guinea pigs infected with Coxiella burnetii strain M-44. The Journal of infectious diseases. 1977; 135(6); 995-998. [PubMed: 864292 ].
  12. Langley et al., 2003: Langley JM, Marrie TJ, Leblanc JC, Almudevar A, Resch L, Raoult D. Coxiella burnetii seropositivity in parturient women is associated with adverse pregnancy outcomes. American journal of obstetrics and gynecology. 2003; 189(1); 228-232. [PubMed: 12861167 ].
  13. Li et al., 2005: Li Q, Niu D, Wen B, Chen M, Qiu L, Zhang J. Protective immunity against Q fever induced with a recombinant P1 antigen fused with HspB of Coxiella burnetii. Annals of the New York Academy of Sciences. 2005; 1063; 130-142. [PubMed: 16481504 ].
  14. Mege et al., 1997: Mege JL, Maurin M, Capo C, Raoult D. Coxiella burnetii: the 'query' fever bacterium. A model of immune subversion by a strictly intracellular microorganism. FEMS microbiology reviews. 1997; 19(4); 209-217. [PubMed: 9167255 ].
  15. Ohkuma and Poole, 1978: Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proceedings of the National Academy of Sciences of the United States of America. 1978; 75(7); 3327-3331. [PubMed: 28524].
  16. Ormsbee, 1969: Ormsbee RA. Rickettsiae (as organisms). Annual review of microbiology. 1969; 23; 275-292. [PubMed: 4899075].
  17. Palmer et al., 1983: Palmer NC, Kierstead M, Key DW, Williams JC, Peacock MG, Vellend H. Placentitis and Abortion in Goats and Sheep in Ontario Caused by Coxiella burnetii. The Canadian veterinary journal. La revue veterinaire canadienne. 1983; 24(2); 60-61. [PubMed: 17422227].
  18. Robinson and Hasty, 1974: Robinson DM, Hasty SE. Production of a potent vaccine from the attenuated M-44 strain of Coxiella burneti. Applied microbiology. 1974; 27(4); 777-783. [PubMed: 4825980 ].
  19. Shannon et al., 2005: Shannon JG, Howe D, Heinzen RA. Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(24); 8722-8727. [PubMed: 15939879 ].
  20. Stoker and Marmion, 1955: Stoker MG, Marmion BP. The spread of Q fever from animals to man; the natural history of a rickettsial disease. Bulletin of the World Health Organization. 1955; 13(5); 781-806. [PubMed: 13284558 ].
  21. Tigertt et al., 1961: Tigertt WD, Beneson AS, Gochenour WS. Airborne Q fever. Bacteriological reviews. 1961; 25; 285-293. [PubMed: 13921201].
  22. Turco et al., 1984: Turco J, Thompson HA, Winkler HH. Interferon-gamma inhibits growth of Coxiella burnetii in mouse fibroblasts. Infection and immunity. 1984; 45(3); 781-783. [PubMed: 6432701 ].
  23. Waag et al., 1997: Waag DM, England MJ, Pitt ML. Comparative efficacy of a Coxiella burnetii chloroform:methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol. Vaccine. 1997; 15(16); 1779-1783. [PubMed: 9364683 ].
  24. Waag et al., 2002: Waag DM, England MJ, Tammariello RF, Byrne WR, Gibbs P, Banfield CM, Pitt ML. Comparative efficacy and immunogenicity of Q fever chloroform:methanol residue (CMR) and phase I cellular (Q-Vax) vaccines in cynomolgus monkeys challenged by aerosol. Vaccine. 2002; 20(19-20); 2623-2634. [PubMed: 12057622 ].
  25. Waag, 2007: Waag DM. Coxiella burnetii: Host and bacterial responses to infection. Vaccine. 2007; 25(42); 7288-7295. [PubMed: 17825460 ].
  26. Waldhalm et al., 1978: Waldhalm DG, Stoenner HG, Simmons RE, Thomas LA. Abortion associated with Coxiella burnetii infection in dairy goats. Journal of the American Veterinary Medical Association. 1978; 173(12); 1580-1581. [PubMed: 748297 ].
  27. Williams and Cantrell, 1982: Williams JC, Cantrell JL. Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice. Infection and immunity. 1982; 35(3); 1091-1102. [PubMed: 7068212].
  28. Williams and Thompson, 1991: Williams JC, Thompson HA. Methods for isolation, amplification, and purification of Coxiella burnetii. 73-115. Q Fever: The Biology of Coxiella burnetii. 1991. CRC Press, .
  29. Williams et al., 1990: Williams JC, Hoover TA, Waag DM, Banerjee-Bhatnagar N, Bolt CR, Scott GH. Antigenic structure of Coxiella burnetii. A comparison of lipopolysaccharide and protein antigens as vaccines against Q fever. Annals of the New York Academy of Sciences. 1990; 590; 370-380. [PubMed: 2378463].
  30. Zamboni et al., 2004: Zamboni DS, Campos MA, Torrecilhas AC, Kiss K, Samuel JE, Golenbock DT, Lauw FN, Roy CR, Almeida IC, Gazzinelli RT. Stimulation of toll-like receptor 2 by Coxiella burnetii is required for macrophage production of pro-inflammatory cytokines and resistance to infection. The Journal of biological chemistry. 2004; 279(52); 54405-54415. [PubMed: 15485838 ].

Ebola virus

  1. Feldmann et al., 2003: Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nature reviews. Immunology. 2003 Aug; 3(8); 677-85. [PubMed: 12974482].
  2. Geisbert et al., 2002: Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging infectious diseases. 2002 May; 8(5); 503-7. [PubMed: 11996686].
  3. Pushko et al., 2000: Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000 Aug 15; 19(1); 142-53. [PubMed: 10924796].
  4. Sullivan et al., 2000: Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000 Nov 30; 408(6812); 605-9. [PubMed: 11117750].
  5. Sullivan et al., 2003a: Sullivan N, Yang ZY, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. Journal of virology. 2003 Sep; 77(18); 9733-7. [PubMed: 12941881].
  6. Sullivan et al., 2003b: Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003 Aug 7; 424(6949); 681-4. [PubMed: 12904795].
  7. Vanderzanden et al., 1998: Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, Jahrling P, Huggins J, Schmaljohn A, Schmaljohn C. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology. 1998 Jun 20; 246(1); 134-44. [PubMed: 9657001].
  8. Wilson et al., 2001: Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology. 2001 Aug 1; 286(2); 384-90. [PubMed: 11485406].
  9. Xu et al., 1998: Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ. Immunization for Ebola virus infection. Nature medicine. 1998 Jan; 4(1); 37-42. [PubMed: 9427604].

Eimeria maxima

  1. Wallach, 1997: Wallach M. The importance of transmission-blocking immunity in the control of infections by apicomplexan parasites. International journal for parasitology. 1997; 27(10); 1159-1167. [PubMed: 9394186].

Eimeria spp.

  1. Shirley et al., 2005: Shirley MW, Smith AL, Tomley FM. The biology of avian Eimeria with an emphasis on their control by vaccination. Advances in parasitology. 2005; 60; 285-330. [PubMed: 16230106].

Eimeria tenella

  1. Williams, 2002: Williams RB. Fifty years of anticoccidial vaccines for poultry (1952-2002). Avian diseases. 2002; 46(4); 775-802. [PubMed: 12495038].

Escherichia coli

  1. Acheson et al., 1996: Acheson DW, Levine MM, Kaper JB, Keusch GT. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infection and immunity. 1996; 64(1); 355-357. [PubMed: 8557364].
  2. Berhanu et al., 2008: Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE. Vaccination of BALB/c Mice with Escherichia coli-expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus Challenge. Journal of virology. 2008; ; . [PubMed: 18199639].
  3. Bielaszewska et al., 1997: Bielaszewska M, Clarke I, Karmali MA, Petric M. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infection and immunity. 1997; 65(7); 2509-2516. [PubMed: 9199412].
  4. Bozic et al., 2006: Bozic F, Lackovic G, Kovsca-Janjatovic A, Smolec O, Valpotic I. Levamisole synergizes experimental F4ac+ Escherichia coli oral vaccine in stimulating ileal Peyer's patch T cells in weaned pigs. Journal of veterinary pharmacology and therapeutics. 2006 Jun; 29(3); 199-204. [PubMed: 16669864].
  5. Butterton et al., 1997: Butterton JR, Ryan ET, Acheson DW, Calderwood SB. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infection and immunity. 1997; 65(6); 2127-2135. [PubMed: 9169742 ].
  6. Daley et al., 2007: Daley A, Randall R, Darsley M, Choudhry N, Thomas N, Sanderson IR, Croft N, Kelly P. Genetically modified enterotoxigenic escherichia coli vaccines induce mucosal immune responses without inflammation. Gut. 2007 Jun 12; ; . [PubMed: 17566016].
  7. Dean-Nystrom et al., 2002: Dean-Nystrom EA, Gansheroff LJ, Mills M, Moon HW, O'Brien AD. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infection and immunity. 2002; 70(5); 2414-2418. [PubMed: 11953378].
  8. Durant et al., 2007: Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infection and immunity. 2007 Apr; 75(4); 1916-25. [PubMed: 17145948 ].
  9. ELBERG and FAUNCE, 1957: ELBERG SS, FAUNCE K Jr. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis. Journal of bacteriology. 1957; 73(2); 211-217. [PubMed: 13416171].
  10. Ghaem-Maghami et al., 2001: Ghaem-Maghami M, Simmons CP, Daniell S, Pizza M, Lewis D, Frankel G, Dougan G. Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium. Infection and immunity. 2001; 69(9); 5597-5605. [PubMed: 11500434 ].
  11. Hagan and Mobley, 2007: Hagan EC, Mobley HL. Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection. Infection and immunity. 2007; 75(8); 3941-3949. [PubMed: 17517861].
  12. Hancock et al., 2008: Hancock V, Ferrières L, Klemm P. The ferric yersiniabactin uptake receptor FyuA is required for efficient biofilm formation by urinary tract infectious Escherichia coli in human urine. Microbiology (Reading, England). 2008; 154(Pt 1); 167-175. [PubMed: 18174135].
  13. Horne et al., 2002: Horne C, Vallance BA, Deng W, Finlay BB. Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines. Expert review of vaccines. 2002; 1(4); 483-493. [PubMed: 12901587 ].
  14. Judge et al., 2004: Judge NA, Mason HS, O'Brien AD. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infection and immunity. 2004 Jan; 72(1); 168-75. [PubMed: 14688094 ].
  15. Langermann et al., 1997: Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science (New York, N.Y.). 1997; 276(5312); 607-611. [PubMed: 9110982].
  16. Leyten et al., 2005: Leyten EM, Soonawala D, Schultsz C, Herzog C, Ligthelm RJ, Wijnands S, Visser LG. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study. Vaccine. 2005; 23(43); 5120-5126. [PubMed: 15982790].
  17. Lynne et al., 2006: Lynne AM, Foley SL, Nolan LK. Immune response to recombinant Escherichia coli Iss protein in poultry. Avian diseases. 2006 Jun; 50(2); 273-6. [PubMed: 16863080].
  18. Marcato et al., 2001: Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, Armstrong GD. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. The Journal of infectious diseases. 2001; 183(3); 435-443. [PubMed: 11133375].
  19. Mason et al., 1998: Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine. 1998; 16(13); 1336-1343. [PubMed: 9682399 ].
  20. Melkebeek et al., 2007: Melkebeek V, Verdonck F, Goddeeris BM, Cox E. Comparison of immune responses in parenteral FaeG DNA primed pigs boosted orally with F4 protein or reimmunized with the DNA vaccine. Veterinary immunology and immunopathology. 2007 Apr 15; 116(3-4); 199-214. [PubMed: 17331591].
  21. Moravec et al., 2007: Moravec T, Schmidt MA, Herman EM, Woodford-Thomas T. Production of Escherichia coli heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine. Vaccine. 2007 Feb 19; 25(9); 1647-57. [PubMed: 17188785].
  22. Pascual et al., 1999: Pascual DW, Hone DM, Hall S, van Ginkel FW, Yamamoto M, Walters N, Fujihashi K, Powell RJ, Wu S, Vancott JL, Kiyono H, McGhee JR. Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response. Infection and immunity. 1999; 67(12); 6249-6256. [PubMed: 10569734 ].
  23. Pathport: Escherichia coli [http://pathport.vbi.vt.edu/pathinfo/]
  24. Potter et al., 2004: Potter AA, Klashinsky S, Li Y, Frey E, Townsend H, Rogan D, Erickson G, Hinkley S, Klopfenstein T, Moxley RA, Smith DR, Finlay BB. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine. 2004; 22(3-4); 362-369. [PubMed: 14670317].
  25. Pubmed: Protein search [http://www.ncbi.nlm.nih.gov.proxy.lib.umich.edu/sites/entrez?db=Protein]
  26. Russo et al., 2007: Russo TA, Beanan JM, Olson R, Genagon SA, MacDonald U, Cope JJ, Davidson BA, Johnston B, Johnson JR. A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate. Vaccine. 2007 May 10; 25(19); 3859-70. [PubMed: 17306426].
  27. Turner et al., 2006: Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, Deary A, Casula G, Daley A, Kelly P, Randall R, Darsley MJ. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I. Infection and immunity. 2006 Feb; 74(2); 1062-71. [PubMed: 16428753].
  28. Van et al., 2005: Van Donkersgoed J, Hancock D, Rogan D, Potter AA. Escherichia coli O157:H7 vaccine field trial in 9 feedlots in Alberta and Saskatchewan. The Canadian veterinary journal. La revue veterinaire canadienne. 2005; 46(8); 724-728. [PubMed: 16187717].
  29. van et al., 2007: van Diemen PM, Dziva F, Abu-Median A, Wallis TS, van den Bosch H, Dougan G, Chanter N, Frankel G, Stevens MP. Subunit vaccines based on intimin and Efa-1 polypeptides induce humoral immunity in cattle but do not protect against intestinal colonisation by enterohaemorrhagic Escherichia coli O157:H7 or O26:H-. Veterinary immunology and immunopathology. 2007 Mar 15; 116(1-2); 47-58. [PubMed: 17258324].
  30. Walker et al., 2007: Walker RI, Steele D, Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine. 2007 Mar 30; 25(14); 2545-66. [PubMed: 17224212].
  31. Wen et al., 2006: Wen SX, Teel LD, Judge NA, O'Brien AD. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proceedings of the National Academy of Sciences of the United States of America. 2006 May 2; 103(18); 7082-7. [PubMed: 16641102].
  32. Wennerås et al., 1992: Wennerås C, Svennerholm AM, Ahrén C, Czerkinsky C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infection and immunity. 1992; 60(7); 2605-2611. [PubMed: 1612730].
  33. Zhang et al., 2006: Zhang J, Shi Z, Kong FK, Jex E, Huang Z, Watt JM, Van Kampen KR, Tang DC. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infection and immunity. 2006 Jun; 74(6); 3607-17. [PubMed: 16714593].

Francisella tularensis

  1. Bakshi et al., 2006: Bakshi CS, Malik M, Regan K, Melendez JA, Metzger DW, Pavlov VM, Sellati TJ. Superoxide dismutase B gene (sodB)-deficient mutants of Francisella tularensis demonstrate hypersensitivity to oxidative stress and attenuated virulence. Journal of bacteriology. 2006 Sep; 188(17); 6443-8. [PubMed: 16923916].
  2. Bakshi et al., 2008: Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine. 2008; 26(41); 5276-5288. [PubMed: 18692537].
  3. Dreisbach et al., 2000: Dreisbach VC, Cowley S, Elkins KL. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infection and immunity. 2000 Apr; 68(4); 1988-96. [PubMed: 10722593].
  4. Elkins et al., 1996: Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infection and immunity. 1996 Aug; 64(8); 3288-93. [PubMed: 8757866].
  5. Hepburn et al., 2006: Hepburn MJ, Purcell BK, Lawler JV, Coyne SR, Petitt PL, Sellers KD, Norwood DA, Ulrich MP. Live vaccine strain Francisella tularensis is detectable at the inoculation site but not in blood after vaccination against tularemia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006 Sep 15; 43(6); 711-6. [PubMed: 16912944].
  6. Isherwood et al., 2005: Isherwood KE, Titball RW, Davies DH, Felgner PL, Morrow WJ. Vaccination strategies for Francisella tularensis. Advanced drug delivery reviews. 2005 Jun 17; 57(9); 1403-14. [PubMed: 15919131].
  7. Jia et al., 2009: Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine. 2009; 27(8); 1216-1229. [PubMed: 19126421].
  8. Lauriano et al., 2003: Lauriano CM, Barker JR, Nano FE, Arulanandam BP, Klose KE. Allelic exchange in Francisella tularensis using PCR products. FEMS microbiology letters. 2003 Dec 12; 229(2); 195-202. [PubMed: 14680699].
  9. Pammit et al., 2006: Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infection and immunity. 2006 Apr; 74(4); 2063-71. [PubMed: 16552035].
  10. Rohmer et al., 2006: Rohmer L, Brittnacher M, Svensson K, Buckley D, Haugen E, Zhou Y, Chang J, Levy R, Hayden H, Forsman M, Olson M, Johansson A, Kaul R, Miller SI. Potential source of Francisella tularensis live vaccine strain attenuation determined by genome comparison. Infection and immunity. 2006 Sep 25; ; . [PubMed: 17000723].
  11. Tempel et al., 2006: Tempel R, Lai XH, Crosa L, Kozlowicz B, Heffron F. Attenuated Francisella novicida transposon mutants protect mice against wild-type challenge. Infection and immunity. 2006 Sep; 74(9); 5095-105. [PubMed: 16926401].
  12. Twine et al., 2005: Twine S, Bystrom M, Chen W, Forsman M, Golovliov I, Johansson A, Kelly J, Lindgren H, Svensson K, Zingmark C, Conlan W, Sjostedt A. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infection and immunity. 2005 Dec; 73(12); 8345-52. [PubMed: 16299332 ].

Giardia duodenalis

  1. Olson et al., 2000: Olson ME, Ceri H, Morck DW. Giardia vaccination. Parasitology today (Personal ed.). 2000; 16(5); 213-217. [PubMed: 10782082].

Haemophilus influenzae

  1. AAPC 1991: American Academy of Pediatrics Committee. American Academy of Pediatrics Committee on Infectious Diseases: Haemophilus influenzae type b conjugate vaccines: recommendations for immunization of infants and children 2 months of age and older: update. Pediatrics. 1991; 88(1); 169-172. [PubMed: 2057256].
  2. ActHIB 2005: Haemophilus b conjugate vaccine ActHIB [http://www.acthib.com]
  3. Bertot et al., 2004: Bertot GM, Becker PD, Guzman CA, Grinstein S. Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. The Journal of infectious diseases. 2004 Apr 1; 189(7); 1304-12. [PubMed: 15031801].
  4. Bolduc et al., 2000: Bolduc GR, Bouchet V, Jiang RZ, Geisselsoder J, Truong-Bolduc QC, Rice PA, Pelton SI, Goldstein R. Variability of outer membrane protein P1 and its evaluation as a vaccine candidate against experimental otitis media due to nontypeable Haemophilus influenzae: an unambiguous, multifaceted approach. Infection and immunity. 2000 Aug; 68(8); 4505-17. [PubMed: 10899849].
  5. Clancy et al., 1985: Clancy R, Cripps A, Murree-Allen K, Yeung S, Engel M. Oral immunisation with killed Haemophilus influenzae for protection against acute bronchitis in chronic obstructive lung disease. Lancet. 1985 Dec 21-28; 2(8469-70); 1395-7. [PubMed: 2867396].
  6. Clancy et al., 1990: Clancy RL, Cripps AW, Gebski V. Protection against recurrent acute bronchitis after oral immunization with killed Haemophilus influenzae. The Medical journal of Australia. 1990 Apr 16; 152(8); 413-6. [PubMed: 2184330].
  7. Clancy et al., 1992: Clancy RL, Cripps AW. Specific protection against acute bronchitis associated with nontypeable Haemophilus influenzae. The Journal of infectious diseases. 1992 Jun; 165 Suppl 1; S194-5. [PubMed: 1588162].
  8. Comvax: Comvax [http://www.fda.gov/cber/products/comvax.htm]
  9. Decker et al., 1992: Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. The Journal of pediatrics. 1992 Feb; 120(2 Pt 1); 184-9. [PubMed: 1735812].
  10. FDA: ACTHIB: FDA: ACTHIB Vaccine for Haemophilus influenzae [http://www.fda.gov/cber/label/acthibLB.pdf]
  11. FDA: COMVAX: FDA: COMVAX information [http://www.fda.gov/CBER/label/hbHB100296Lb.pdf]
  12. Foxwell et al., 2006: Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane database of systematic reviews (Online). 2006 Oct 18; (4); CD001958. [PubMed: 17054150 ].
  13. Fritzell et al., 1992: Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. The Journal of pediatrics. 1992 Sep; 121(3); 355-62. [PubMed: 1517908].
  14. Green et al., 1991: Green BA, Farley JE, Quinn-Dey T, Deich RA, Zlotnick GW. The e (P4) outer membrane protein of Haemophilus influenzae: biologic activity of anti-e serum and cloning and sequencing of the structural gene. Infection and immunity. 1991 Sep; 59(9); 3191-8. [PubMed: 1715322 ].
  15. Gu et al., 1996: Gu XX, Tsai CM, Ueyama T, Barenkamp SJ, Robbins JB, Lim DJ. Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins. Infection and immunity. 1996 Oct; 64(10); 4047-53. [PubMed: 8926067 ].
  16. Gu et al., 1997: Gu XX, Sun J, Jin S, Barenkamp SJ, Lim DJ, Robbins JB, Battey J. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas. Infection and immunity. 1997; 65(11); 4488-4493. [PubMed: 9353024].
  17. Gu et al., 2003: Gu XX, Rudy SF, Chu C, McCullagh L, Kim HN, Chen J, Li J, Robbins JB, Van Waes C, Battey JF. Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine. 2003 May 16; 21(17-18); 2107-14. [PubMed: 12706701].
  18. HibTITER 2007: HAEMOPHILUS b CONJUGATE VACCINE (Diphtheria CRM197 Protein Conjugate) HibTITER® [http://www.wyeth.com/content/showlabeling.asp?id=105]
  19. Hotomi et al., 2005: Hotomi M, Ikeda Y, Suzumoto M, Yamauchi K, Green BA, Zlotnick G, Billal DS, Shimada J, Fujihara K, Yamanaka N. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine. 2005 Jan 26; 23(10); 1294-300. [PubMed: 15652672].
  20. Kayhty et al., 1984: Kayhty H, Karanko V, Peltola H, Makela PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics. 1984 Nov; 74(5); 857-65. [PubMed: 6387614].
  21. Kilian et al, 1991: Kilian, M. Haemophilus. 463-470. Manual of clinical microbiology, 5th ed. 1991. American Society for Microbiology, Washington, DC.
  22. Kurono et al., 1999: Kurono Y, Yamamoto M, Fujihashi K, Kodama S, Suzuki M, Mogi G, McGhee JR, Kiyono H. Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. The Journal of infectious diseases. 1999 Jul; 180(1); 122-32. [PubMed: 10353870].
  23. Kyd and Cripps, 1998: Kyd JM, Cripps AW. Potential of a novel protein, OMP26, from nontypeable Haemophilus influenzae to enhance pulmonary clearance in a rat model. Infection and immunity. 1998; 66(5); 2272-2278. [PubMed: 9573117].
  24. Kyd et al., 2003: Kyd JM, Cripps AW, Novotny LA, Bakaletz LO. Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infection and immunity. 2003 Aug; 71(8); 4691-9. [PubMed: 12874350].
  25. Lehmann et al., 1991: Lehmann D, Coakley KJ, Coakley CA, Spooner V, Montgomery JM, Michael A, Riley ID, Smith T, Clancy RL, Cripps AW. Reduction in the incidence of acute bronchitis by an oral Haemophilus influenzae vaccine in patients with chronic bronchitis in the highlands of Papua New Guinea. The American review of respiratory disease. 1991 Aug; 144(2); 324-30. [PubMed: 1859055].
  26. Lepow et al., 1987: Lepow ML, Barkin RM, Berkowitz CD, Brunell PA, James D, Meier K, Ward J, Zahradnik JM, Samuelson J, McVerry PH. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) in infants. The Journal of infectious diseases. 1987 Oct; 156(4); 591-6. [PubMed: 3497990 ].
  27. Liu et al., 2004: Liu DF, Mason KW, Mastri M, Pazirandeh M, Cutter D, Fink DL, St Geme JW 3rd, Zhu D, Green BA. The C-terminal fragment of the internal 110-kilodalton passenger domain of the Hap protein of nontypeable Haemophilus influenzae is a potential vaccine candidate. Infection and immunity. 2004 Dec; 72(12); 6961-8. [PubMed: 15557618].
  28. Makwana et al., 2007: Makwana N, Riordan FA. Bacterial meningitis: the impact of vaccination. CNS drugs. 2007; 21(5); 355-66. [PubMed: 17447825].
  29. Marburg 1986: S. Marburg, D. Jorn, R. L. Tolman, B. Arison, J. McCauley, P. J. Kniskern, A. Hagopian, and P. P. Vella. Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. Journal of the American Chemical Society. 1986; 108; 5282-5287.
  30. Marrs et al., 2001: Marrs CF, Krasan GP, McCrea KW, Clemans DL, Gilsdorf JR. Haemophilus influenzae - human specific bacteria. Frontiers in bioscience : a journal and virtual library. 2001 Sep 1; 6; E41-60. [PubMed: 11532609].
  31. Mason et al., 2004: Mason KW, Zhu D, Scheuer CA, McMichael JC, Zlotnick GW, Green BA. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. Vaccine. 2004 Sep 3; 22(25-26); 3449-56. [PubMed: 15308371].
  32. McMahon et al., 2005: McMahon M, Murphy TF, Kyd J, Thanavala Y. Role of an immunodominant T cell epitope of the P6 protein of nontypeable Haemophilus influenzae in murine protective immunity. Vaccine. 2005 May 20; 23(27); 3590-6. [PubMed: 15855018].
  33. Meekison et al., 1989: Meekison W, Hutcheon M, Guasparini R, Arnott M, Scheifele D, Grace M, Humphreys G, Barreto L. Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia. Canada diseases weekly report = Rapport hebdomadaire des maladies au Canada. 1989 Jul 15; 15(28); 143-5. [PubMed: 2791073].
  34. PedvasHIB: Liquid PedvaxHIB [http://www.merck.com/product/usa/pi_circulars/p/pedvax_hib]
  35. Peltola et al., 1977: Peltola H, Kayhty H, Sivonen A, Makela H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics. 1977 Nov; 60(5); 730-7. [PubMed: 335348].
  36. ProHIBiT 2007: Haemophilus b Conjugate Vaccine (Diphtheria Toxoid-Conjugate) [http://www.rxlist.com/cgi/generic/prohibit.htm]
  37. Reinholdt et al., 1997: Reinholdt J, Kilian M. Comparative analysis of immunoglobulin A1 protease activity among bacteria representing different genera, species, and strains. Infection and immunity. 1997 Nov; 65(11); 4452-9. [PubMed: 9353019].
  38. Riedmann et al., 2003: Riedmann EM, Kyd JM, Smith AM, Gomez-Gallego S, Jalava K, Cripps AW, Lubitz W. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts--a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS immunology and medical microbiology. 2003 Jul 15; 37(2-3); 185-92. [PubMed: 12832124].
  39. Rothstein et al., 1991: Rothstein EP, Madore DV, Long SS. Antibody persistence four years after primary immunization of infants and toddlers with Haemophilus influenzae type b CRM197 conjugate vaccine. The Journal of pediatrics. 1991 Oct; 119(4); 655-7. [PubMed: 1919902].
  40. Sabirov et al., 2004: Sabirov A, Kodama S, Sabirova N, Mogi G, Suzuki M. Intranasal immunization with outer membrane protein P6 and cholera toxin induces specific sinus mucosal immunity and enhances sinus clearance of nontypeable Haemophilus influenzae. Vaccine. 2004 Aug 13; 22(23-24); 3112-21. [PubMed: 15297063].
  41. Talan et al., 1999: Talan DA, Moran GJ, Pinner RW. Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. Annals of emergency medicine. 1999 Jul; 34(1); 109-11. [PubMed: 10382005].
  42. Tandon et al., 1991: Tandon MK, Gebski V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. Australian and New Zealand journal of medicine. 1991 Aug; 21(4); 427-32. [PubMed: 1953532].
  43. Tristram et al., 2007: Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clinical microbiology reviews. 2007 Apr; 20(2); 368-89. [PubMed: 17428889 ].
  44. Webb et al., 1999: Webb DC, Cripps AW. Immunization with recombinant transferrin binding protein B enhances clearance of nontypeable Haemophilus influenzae from the rat lung. Infection and immunity. 1999 May; 67(5); 2138-44. [PubMed: 10225866].
  45. Webb et al., 2000: Webb DC, Cripps AW. A P5 peptide that is homologous to peptide 10 of OprF from Pseudomonas aeruginosa enhances clearance of nontypeable Haemophilus influenzae from acutely infected rat lung in the absence of detectable peptide-specific antibody. Infection and immunity. 2000 Jan; 68(1); 377-81. [PubMed: 10603411].
  46. Weinberg et al., 1988: Weinberg GA, Granoff DM. Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. The Journal of pediatrics. 1988 Oct; 113(4); 621-31. [PubMed: 3050001 ].
  47. Wu et al., 2005: Wu T, Chen J, Murphy TF, Green BA, Gu XX. Investigation of non-typeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines. Vaccine. 2005 Oct 25; 23(44); 5177-85. [PubMed: 16039021].
  48. Zagursky et al., 2000: Zagursky RJ, Ooi P, Jones KF, Fiske MJ, Smith RP, Green BA. Identification of a Haemophilus influenzae 5'-nucleotidase protein: cloning of the nucA gene and immunogenicity and characterization of the NucA protein. Infection and immunity. 2000 May; 68(5); 2525-34. [PubMed: 10768940].

Hantavirus

  1. CDC Hantaviruses: CDC Hantaviruses [http://0-www.cdc.gov.mill1.sjlibrary.org/ncidod/diseases/hanta/hps/]
  2. Custer et al., 2003: Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. Journal of virology. 2003 Sep; 77(18); 9894-905. [PubMed: 12941899 ].
  3. de et al., 2002: de Carvalho Nicacio C, Gonzalez Della Valle M, Padula P, Bjorling E, Plyusnin A, Lundkvist A. Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. Journal of virology. 2002 Jul; 76(13); 6669-77. [PubMed: 12050380].
  4. Klingstrom et al., 2004: Klingstrom J, Maljkovic I, Zuber B, Rollman E, Kjerrstrom A, Lundkvist A. Vaccination of C57/BL6 mice with Dobrava hantavirus nucleocapsid protein in Freund's adjuvant induced partial protection against challenge. Vaccine. 2004 Sep 28; 22(29-30); 4029-34. [PubMed: 15364453].
  5. Kruger et al., 2001: Kruger DH, Ulrich R, Lundkvist A A. Hantavirus infections and their prevention. Microbes and infection / Institut Pasteur. 2001 Nov; 3(13); 1129-44. [PubMed: 11709294 ].
  6. Lednicky, 2003: Lednicky JA. Hantaviruses. a short review. Archives of pathology & laboratory medicine. 2003 Jan; 127(1); 30-5. [PubMed: 12521363].
  7. Maes et al., 2006: Maes P, Keyaerts E, Bonnet V, Clement J, Avsic-Zupanc T, Robert A, Van Ranst M. Truncated recombinant Dobrava hantavirus nucleocapsid proteins induce strong, long-lasting immune responses in mice. Intervirology. 2006; 49(5); 253-60. [PubMed: 16714853].
  8. Ulrich et al., 1998: Ulrich R, Lundkvist A, Meisel H, Koletzki D, Sjolander KB, Gelderblom HR, Borisova G, Schnitzler P, Darai G, Kruger DH. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine. 1998 Jan-Feb; 16(2-3); 272-80. [PubMed: 9607042 ].

Hepatitis A virus

  1. EMC: Avaxim: The electronic Medicines Compendium: Avaxim [http://emc.medicines.org.uk/medicine/17385/PIL/AVAXIM/]
  2. EMC: Epaxal: EMC: Epaxal Product Information [http://emc.medicines.org.uk/medicine/12742/SPC/Epaxal/]
  3. FDA: Havrix: FDA: Havrix vaccine information [http://www.fda.gov/Cber/products/havrix.htm]
  4. FDA: HAVRIX: FDA: HAVRIX Influenza Virus Vaccine [http://www.fda.gov/cber/label/havrixLB.pdf]
  5. FDA: TWINRIX: FDA: TWINRIX Influenze Virus Vaccine [http://www.fda.gov/cber/label/hahbgsk032807LB.pdf]
  6. FDA: VAQTA: FDA: VAQTA vaccine information [http://www.fda.gov/Cber/products/vaqta.htm]
  7. GSK: Twinrix: GSK: Twinrix Product information [http://www.gsk.ca/english/docs-pdf/Twinrix_PM_20080916_EN.pdf]
  8. SP: Avaxim Pediatrix: SP: Avaxim Pediatrix [https://www.vaccineshoppecanada.com/secure/pdfs/ca/Avaxim_Ped_E.pdf]
  9. Wiki: Hepatitis A: Wiki: Hepatitis A virus [http://en.wikipedia.org/wiki/Hepatitis_A_virus]

Hepatitis B virus

  1. FDA: ENGERIX-B: FDA: ENGERIX-B Influenza Virus Vaccine [http://www.fda.gov/cber/label/hepbgsk013007LB.pdf]
  2. FDA: RECOMBIVAX HB: FDA: RECOMBIVAX HB Influenza Virus Vaccine [http://www.fda.gov/cber/label/recombihbLB.pdf]
  3. FDA: TWINRIX: FDA: TWINRIX Influenza Virus Vaccine [http://www.fda.gov/cber/label/hahbgsk032807LB.pdf]
  4. Merck: Recombivax HB: Merck: Recombivax HB vaccine information [http://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf]
  5. Wiki: Hepatitis B: Wiki: Hepatitis B virus [http://en.wikipedia.org/wiki/Hepatitis_B]

Human Immunodeficiency Virus

  1. Ayyavoo et al., 2002: Ayyavoo V, Muthumani K, Kudchodkar S, Zhang D, Ramanathan P, Dayes NS, Kim JJ, Sin JI, Montaner LJ, Weiner DB. HIV-1 viral protein R compromises cellular immune function in vivo. International immunology. 2002 Jan; 14(1); 13-22. [PubMed: 11751747].
  2. Bielinska et al., 2008: Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS research and human retroviruses. 2008; 24(2); 271-281. [PubMed: 18260780].
  3. Buchbinder et al., 1994: Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS (London, England). 1994 Aug; 8(8); 1123-8. [PubMed: 7986410].
  4. Caley et al., 1999: Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine. 1999 Aug 6; 17(23-24); 3124-35. [PubMed: 10462249].
  5. Chan et al., 1997: Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997 Apr 18; 89(2); 263-73. [PubMed: 9108481].
  6. Chen et al., 2005: Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE Jr, Marovich M, Spearman P. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. Journal of virology. 2005 May; 79(9); 5537-47. [PubMed: 15827168].
  7. Coakley et al., 2005: Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Current opinion in infectious diseases. 2005 Feb; 18(1); 9-15. [PubMed: 15647694].
  8. Coffin et al., 1986: Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P. What to call the AIDS virus?. Nature. 1986 May 1-7; 321(6065); 10. [PubMed: 3010128].
  9. Davis et al., 2002: Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, Maughan M, Connell M, Walker C, McGrath K, Cecil C, Ping LH, Frelinger J, Olmsted R, Keith P, Swanstrom R, Williamson C, Johnson P, Montefiori D, Johnston RE. Alphavirus replicon particles as candidate HIV vaccines. IUBMB life. 2002 Apr-May; 53(4-5); 209-11. [PubMed: 12120997].
  10. Deng et al., 1996: Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996 Jun 20; 381(6584); 661-6. [PubMed: 8649511].
  11. Durier et al., 2006: Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, Guillet JG, Pialoux G, Aboulker JP. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS (London, England). 2006 Apr 24; 20(7); 1039-49. [PubMed: 16603857].
  12. Kent et al., 2007: Kent S, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Current opinion in investigational drugs (London, England : 2000). 2007 Feb; 8(2); 159-67. [PubMed: 17328232].
  13. Knight et al., 1990: Knight SC, Macatonia SE, Patterson S. HIV I infection of dendritic cells. International reviews of immunology. 1990; 6(2-3); 163-75. [PubMed: 2152500].
  14. Liu et al., 2004: Liu YZ, Zhou L, Wang Q, Ye SQ, Li HX, Zeng Y. [Immune response induced by HIV DNA vaccine combined with recombinant adeno-associated virus]. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2004 Sep; 18(3); 251-4. [PubMed: 15640860].
  15. Liu et al., 2006: Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine. Vaccine. 2006 Apr 12; 24(16); 3332-9. [PubMed: 16472543].
  16. Lu et al., 2000: Lu Y, Friedman R, Kushner N, Doling A, Thomas L, Touzjian N, Starnbach M, Lieberman J. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proceedings of the National Academy of Sciences of the United States of America. 2000 Jul 5; 97(14); 8027-32. [PubMed: 10884430].
  17. Malm et al., 2005: Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral immunology. 2005; 18(4); 678-88. [PubMed: 16359234].
  18. McEvers et al., 2005: McEvers K, Elrefaei M, Norris P, Deeks S, Martin J, Lu Y, Cao H. Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways. Vaccine. 2005 Jul 14; 23(32); 4128-35. [PubMed: 15964481].
  19. Otten et al., 2005: Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, O'Hagan DT, Barnett S, Ulmer JB. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. Journal of virology. 2005 Jul; 79(13); 8189-200. [PubMed: 15956564].
  20. Palella et al., 1998: Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England journal of medicine. 1998 Mar 26; 338(13); 853-60. [PubMed: 9516219].
  21. Santra et al., 2004: Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America. 2004 Jul 27; 101(30); 11088-93. [PubMed: 15258286].
  22. Shiver et al., 2002: Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002 Jan 17; 415(6869); 331-5. [PubMed: 11797011].
  23. Takehisa et al., 2001: Takehisa J, Harada Y, Ndembi N, Mboudjeka I, Taniguchi Y, Ngansop C, Kuate S, Zekeng L, Ibuki K, Shimada T, Bikandou B, Yamaguchi-Kabata Y, Miura T, Ikeda M, Ichimura H, Kaptue L, Hayami M. Natural infection of wild-born mandrills (Mandrillus sphinx) with two different types of simian immunodeficiency virus. AIDS research and human retroviruses. 2001 Aug 10; 17(12); 1143-54. [PubMed: 11522184].
  24. Tatalick et al., 2005: Tatalick LM, Gerard CJ, Takeya R, Price DN, Thorne BA, Wyatt LM, Anklesaria P. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine. Vaccine. 2005 Apr 8; 23(20); 2628-38. [PubMed: 15780446].
  25. Xin et al., 2005: Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, Kitamura K, Hayakawa T, Saha S, Takeshita F, Okuda K, Honda M, Klinman DM, Okuda K. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene therapy. 2005 Dec; 12(24); 1769-77. [PubMed: 16079886].

Human papillomavirus

  1. FDA: Cevarix: FDA: Cervarix [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm]
  2. FDA: Gardasil: FDA: Gardasil information [http://www.fda.gov/Cber/products/gardasil.htm]
  3. Huang, 2008: Huang CM. Human papillomavirus and vaccination. Mayo Clinic proceedings. Mayo Clinic. 2008; 83(6); 701-706; quiz 706-706. [PubMed: 18533087].
  4. Panagiotis et al., 2008: Panagiotis C, Efthimios D, Konstantinos P, George C. Human papilloma virus: diagnostic, treatment and preventive issues. Akusherstvo i ginekologiia. 2008; 47(1); 35-38. [PubMed: 18642576].

Influenza virus

  1. Afluria webpage: Afluria official web page [http://www.afluria.com/]
  2. Block et al., 2008: Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine. 2008; 26(38); 4940-4946. [PubMed: 18662737].
  3. Bublot et al., 2006: Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, Audonnet JC, Mickle TR. Development and use of fowlpox vectored vaccines for avian influenza. Annals of the New York Academy of Sciences. 2006; 1081; 193-201. [PubMed: 17135511].
  4. FDA: Afluria: FDA: Afluria influenza virus vaccine information [http://www.fda.gov/CbER/label/afluriaLB.pdf]
  5. FDA: Agriflu: FDA: Agriflu [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM192127.pdf]
  6. FDA: CSL H1N1 vaccine: FDA: the H1N1 influenza vaccine from CSL [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181975.htm]
  7. FDA: Fluarix: FDA: Fluarix Package Insert [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM112920.pdf]
  8. FDA: Flulaval: FDA Flulaval information [http://www.fda.gov/CbER/label/flulavalLB.pdf]
  9. FDA: FluLaval: FDA FluLaval information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112845.htm]
  10. FDA: Flulaval Approval: FDA: Flulaval approval information [http://www.fda.gov/cber/products/flulaval.htm]
  11. FDA: Flumist: FDA: Flumist Influenza Virus Vaccine [http://www.fda.gov/CbER/label/flumistLB.pdf]
  12. FDA: Fluvirin: FDA: Fluvirin Influenza Virus Vaccine [http://www.fda.gov/CbER/label/fluvirinLB.pdf]
  13. FDA: Fluzone: FDA: Fluzone influenza vaccine information [http://www.fda.gov/CbER/label/fluzoneLB.pdf]
  14. FDA: Fluzone HD: FDA: Fluzone High-dose [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM195479.pdf]
  15. FDA: H1N1 Novartis Vaccine: FDA H1N1 Influenza Vaccine from Novartis Vaccines and Diagnostics Ltd [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181973.htm]
  16. FDA: H1N1 Vaccine Sanofi Pasteur: FDA: H1N1 Influenza virus vaccine from Sanofi Pasteur [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm181971.htm]
  17. FDA: MedImmune H1N1 vaccine: Influenza A (H1N1) 2009 Monovalent Vaccine (MedImmune LLC) [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM182406.pdf]
  18. FDA: Sanofi Pasteur H5N1: FDA: Sanofi Pasteur H5N1Influenza virus vaccine information [http://www.fda.gov/CbER/label/h5n1san041707LB.pdf]
  19. FluMist website: FluMist official website [http://www.flumist.com/]
  20. GSK: Fluviral S/F: Fluviral Product Monograph [http://www.gsk.ca/english/docs-pdf/Fluviral_2009_PM.pdf]
  21. GSK: US Fluarix: GSK: US Fluarix vaccine information [http://us.gsk.com/products/assets/us_fluarix.pdf]
  22. Minke et al., 2004: Minke JM, Audonnet JC, Fischer L. Equine viral vaccines: the past, present and future. Veterinary research. 2004; 35(4); 425-443. [PubMed: 15236675].
  23. Park et al., 2006: Park MS, Steel J, García-Sastre A, Swayne D, Palese P. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(21); 8203-8208. [PubMed: 16717196].
  24. Solvay Website: Influvac Manufacter Website [http://www.solvay-influenza.com/aboutvaccination/faqs/0,,2659-2-0,00.htm#7]
  25. Vaxigrip Package Insert: Vaxigrip Package Insert [http://www.novaccine.com/pdffiles/vaxigrip_package_insert.pdf]
  26. Veits et al., 2006: Veits J, Wiesner D, Fuchs W, Hoffmann B, Granzow H, Starick E, Mundt E, Schirrmeier H, Mebatsion T, Mettenleiter TC, Römer-Oberdörfer A. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(21); 8197-8202. [PubMed: 16717197].
  27. Wiki: Influenza: Wiki: Influenza [http://en.wikipedia.org/wiki/Influenza]

Japanese encephalitis virus

  1. FDA: Ixiaro: FDA: Ixiaro [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142570.pdf]
  2. FDA: JE-Vax: FDA: JE-Vax vaccine information [http://www.fda.gov/cber/products/jevax.htm]
  3. Wiki: Japanese encephalitis: Wiki: Japanese encephalitis [http://en.wikipedia.org/wiki/Japanese_encephalitis]

Lassa Fever Virus

  1. Auperin et al., 1988: Auperin DD, Esposito JJ, Lange JV, Bauer SP, Knight J, Sasso DR, McCormick JB. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus research. 1988 Feb; 9(2-3); 233-48. [PubMed: 3354260].
  2. Botten et al., 2006: Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, Ting J, Peters B, Southwood S, Stewart B, Rodriguez-Carreno MP, Mothe B, Whitton JL, Sette A, Buchmeier MJ. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. Journal of virology. 2006 Sep; 80(17); 8351-61. [PubMed: 16912286].
  3. Bredenbeek et al., 2006: Bredenbeek PJ, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, Salvato MS, Moshkoff D, Zapata J, Tikhonov I, Patterson J, Carrion R, Ticer A, Brasky K, Lukashevich IS. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology. 2006 Feb 20; 345(2); 299-304. [PubMed: 16412488].
  4. Fisher-Hoch et al., 2000: Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for lassa fever. Journal of virology. 2000 Aug; 74(15); 6777-83. [PubMed: 10888616].
  5. Fisher-Hoch et al., 2001: Fisher-Hoch SP, McCormick JB. Towards a human Lassa fever vaccine. Reviews in medical virology. 2001 Sep-Oct; 11(5); 331-41. [PubMed: 11590670].
  6. Geisbert et al., 2005: Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Stroher U, Fernando L, Daddario KM, Guttieri MC, Mothe BR, Larsen T, Hensley LE, Jahrling PB, Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS medicine. 2005 Jun; 2(6); e183. [PubMed: 15971954].
  7. Lukashevich et al., 2005: Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, Salvato MS. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. Journal of virology. 2005 Nov; 79(22); 13934-42. [PubMed: 16254329].

Lawsonia intracellularis

  1. Guedes and Gebhart, 2003: Guedes RM, Gebhart CJ. Onset and duration of fecal shedding, cell-mediated and humoral immune responses in pigs after challenge with a pathogenic isolate or attenuated vaccine strain of Lawsonia intracellularis. Veterinary microbiology. 2003; 91(2-3); 135-145. [PubMed: 12458163].
  2. Kroll et al., 2004: Kroll JJ, Roof MB, McOrist S. Evaluation of protective immunity in pigs following oral administration of an avirulent live vaccine of Lawsonia intracellularis. American journal of veterinary research. 2004; 65(5); 559-565. [PubMed: 15141873].

Leishmania donovani

  1. Borja-Cabrera et al., 2002: Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Gomes EM, Luz KG, Palatnik M, Palatnik de Sousa CB. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine. 2002; 20(27-28); 3277-3284. [PubMed: 12213397].

Marburg Virus

  1. Bausch et al., 2007: Bausch DG, Geisbert TW. Development of vaccines for Marburg hemorrhagic fever. Expert review of vaccines. 2007 Feb; 6(1); 57-74. [PubMed: 17280479].
  2. Daddario-DiCaprio et al., 2006: Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, Grolla A, Fritz EA, Feldmann F, Feldmann H, Jones SM. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. Journal of virology. 2006; 80(19); 9659-9666. [PubMed: 16973570].
  3. Hevey et al., 1997: Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 1997 Dec 8; 239(1); 206-16. [PubMed: 9426460 ].
  4. Hevey et al., 1998: Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 1998 Nov 10; 251(1); 28-37. [PubMed: 9813200 ].
  5. Mohamadzadeh et al., 2007: Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nature reviews. Immunology. 2007; 7(7); 556-567. [PubMed: 17589545].
  6. Riemenschneider et al., 2003: Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D, Bray M, Ruff A, Ivins B, Bassett A, Rossi C, Schmaljohn C. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 2003; 21(25-26); 4071-4080. [PubMed: 12922144 ].
  7. Swenson et al., 2005: Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine. 2005; 23(23); 3033-3042. [PubMed: 15811650].
  8. Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
  9. Warfield et al., 2004: Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine. 2004 Sep 3; 22(25-26); 3495-502. [PubMed: 15308377 ].

Marek’s disease virus

  1. Darteil et al., 1995: Darteil R, Bublot M, Laplace E, Bouquet JF, Audonnet JC, Rivière M. Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens. Virology. 1995; 211(2); 481-490. [PubMed: 7645252].

Measles virus

  1. FDA: Attenuvax: FDA: Attenuvax information [http://www.fda.gov/CbER/products/attenuvax.htm]
  2. FDA: MMR-II: FDA: MMR-II [http://www.fda.gov/cber/label/mmriiLB.pdf]
  3. FDA: ProQuad: FDA: ProQuad Vaccine [http://www.fda.gov/cber/label/proquadLB.pdf]
  4. Griffin et al., 2008: Griffin DE, Pan CH, Moss WJ. Measles vaccines. Frontiers in bioscience : a journal and virtual library. 2008; 13; 1352-1370. [PubMed: 17981635].
  5. GSK: Priorix: GSK: Priorix Product Information [http://www.gsk.ca/english/docs-pdf/Priorix_PM_20081103_EN.pdf]
  6. GSK: Priorix-Tetra: GSK: Priorix-Tetra Product Information [http://www.gsk.ca/english/docs-pdf/Priorix-Tetra_PM_20090908_EN.pdf]
  7. Yanagi et al., 2006: Yanagi Y, Takeda M, Ohno S. Measles virus: cellular receptors, tropism and pathogenesis. The Journal of general virology. 2006; 87(Pt 10); 2767-2779. [PubMed: 16963735].

Mumps virus

  1. FDA: MMR-II: FDA: MMR-II [http://www.fda.gov/cber/label/mmriiLB.pdf]
  2. FDA: ProQuad: FDA: ProQuad Vaccine [http://www.fda.gov/cber/label/proquadLB.pdf]
  3. Hviid et al., 2008: Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008; 371(9616); 932-944. [PubMed: 18342688].
  4. Merck: Mumpsvax: Merck: Mumpsvax information [http://www.merck.com/product/usa/pi_circulars/m/mumpsvax/mumpsvax_pi.pdf]

Mycobacterium tuberculosis

  1. Agger et al., 2002: Agger EM, Andersen P. A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine. 2002 Nov 22; 21(1-2); 7-14. [PubMed: 12443657 ].
  2. Chandra et al., 2006: Chandra S, Kaur M, Midha S, Bhatnagar R, Banerjee-Bhatnagar N. Evaluation of the ability of N-terminal fragment of lethal factor of Bacillus anthracis for delivery of Mycobacterium T cell antigen ESAT-6 into cytosol of antigen presenting cells to elicit effective cytotoxic T lymphocyte response. Biochemical and biophysical research communications. 2006 Dec 22; 351(3); 702-7. [PubMed: 17084814 ].
  3. Collins et al., 2005: Collins DM, Skou B, White S, Bassett S, Collins L, For R, Hurr K, Hotter G, de Lisle GW. Generation of attenuated Mycobacterium bovis strains by signature-tagged mutagenesis for discovery of novel vaccine candidates. Infection and immunity. 2005 Apr; 73(4); 2379-86. [PubMed: 15784584].
  4. De et al., 1999: De Lisle GW, Wilson T, Collins DM, Buddle BM. Vaccination of guinea pigs with nutritionally impaired avirulent mutants of Mycobacterium bovis protects against tuberculosis. Infection and immunity. 1999 May; 67(5); 2624-6. [PubMed: 10225931 ].
  5. Ducati et al., 2006: Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption-- a review on tuberculosis. Memorias do Instituto Oswaldo Cruz. 2006 Nov; 101(7); 697-714. [PubMed: 17160276].
  6. Ernst et al., 2007: Ernst JD, Trevejo-Nunez G, Banaiee N. Genomics and the evolution, pathogenesis, and diagnosis of tuberculosis. The Journal of clinical investigation. 2007 Jul; 117(7); 1738-45. [PubMed: 17607348].
  7. Fletcher, 2007: Fletcher HA. Correlates of immune protection from tuberculosis. Current molecular medicine. 2007 May; 7(3); 319-25. [PubMed: 17504116].
  8. Fonseca et al., 2001: Fonseca DP, Benaissa-Trouw B, van Engelen M, Kraaijeveld CA, Snippe H, Verheul AF. Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein. Infection and immunity. 2001 Aug; 69(8); 4839-45. [PubMed: 11447158].
  9. Gartner et al., 2008: Gartner T, Romano M, Suin V, Kalai M, Korf H, De Baetselier P, Huygen K. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine co-expressing pro-apoptotic caspase-3. Vaccine. 2008; 26(11); 1458-1470. [PubMed: 18280621].
  10. Grode et al., 2005: Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, van Soolingen D, Raupach B, Kaufmann SH. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. The Journal of clinical investigation. 2005; 115(9); 2472-2479. [PubMed: 16110326].
  11. Gupta et al., 2007: Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine. 2007 May 10; 25(19); 3742-51. [PubMed: 17321015].
  12. Hamasur et al., 2003: Hamasur B, Haile M, Pawlowski A, Schroder U, Williams A, Hatch G, Hall G, Marsh P, Kallenius G, Svenson SB. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine. 2003 Sep 8; 21(25-26); 4081-93. [PubMed: 12922145].
  13. Hess et al., 1998: Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proceedings of the National Academy of Sciences of the United States of America. 1998 Apr 28; 95(9); 5299-304. [PubMed: 9560270].
  14. Hess et al., 1999: Hess J, Kaufmann SH. Live antigen carriers as tools for improved anti-tuberculosis vaccines. FEMS immunology and medical microbiology. 1999 Feb; 23(2); 165-73. [PubMed: 10076914 ].
  15. Hinchey et al., 2007: Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, Chen B, Chan J, Braunstein M, Orme IM, Derrick SC, Morris SL, Jacobs WR, Porcelli SA. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. The Journal of clinical investigation. 2007 Aug 1; 117(8); 2279-2288. [PubMed: 17671656].
  16. Horwitz et al., 2000: Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proceedings of the National Academy of Sciences of the United States of America. 2000 Dec 5; 97(25); 13853-8. [PubMed: 11095745].
  17. Im et al., 2007: Im EJ, Saubi N, Virgili G, Sander C, Teoh D, Gatell JM, McShane H, Joseph J, Hanke T. Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of HIV-1 through Breastfeeding. Journal of virology. 2007 Jun 27; ; . [PubMed: 17596303].
  18. Kamath et al., 1999: Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infection and immunity. 1999 Apr; 67(4); 1702-7. [PubMed: 10085007].
  19. Kaufmann, 2005: Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends in immunology. 2005 Dec; 26(12); 660-7. [PubMed: 16246622 ].
  20. Khera et al., 2005: Khera A, Singh R, Shakila H, Rao V, Dhar N, Narayanan PR, Parmasivan CN, Ramanathan VD, Tyagi AK. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine. 2005 Dec 1; 23(48-49); 5655-65. [PubMed: 16157425 ].
  21. Martin et al., 2006: Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, Soto CY, Clark SO, Hatch GJ, Aguilar D, Ausina V, Gicquel B. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine. 2006 Apr 24; 24(17); 3408-19. [PubMed: 16564606 ].
  22. McShane et al., 2005: McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinburgh, Scotland). 2005 Jan-Mar; 85(1-2); 47-52. [PubMed: 15687027].
  23. Mollenkopf et al., 2001: Mollenkopf HJ, Groine-Triebkorn D, Andersen P, Hess J, Kaufmann SH. Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA. Vaccine. 2001 Jul 16; 19(28-29); 4028-35. [PubMed: 11427279].
  24. Olsen et al., 2001: Olsen, A.W., L.A.H. van Pinxteren, P.B Rasmussen, and P. Andersen. Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6. Infect. Immun.. 2001; 69(5); 2773-2778.
  25. Perez et al., 2001: Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Molecular microbiology. 2001 Jul; 41(1); 179-87. [PubMed: 11454210].
  26. Skeiky et al., 2004: Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, Campos-Neto A, Lobet Y, Dalemans W, Orme IM, Reed SG. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. Journal of immunology (Baltimore, Md. : 1950). 2004 Jun 15; 172(12); 7618-28. [PubMed: 15187142].
  27. Stephens et al., 2007: Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007; 369(9580); 2196-2210. [PubMed: 17604802].
  28. Sugawara et al., 2007: Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T. Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 2007 Aug 24; ; . [PubMed: 17720625 ].
  29. SWEDBERG, 1951: SWEDBERG B. Studies in experimental tuberculosis; an investigation of some problems of immunity and resistance. Acta medica Scandinavica. Supplementum. 1951; 254; 1-120. [PubMed: 14837707].
  30. Verreck et al., 2001: Verreck FA, de Vries RR, Ottenhoff TH. Setting a course for intervening in host-pathogen interactions. Trends in immunology. 2001 Nov; 22(11); 588-90. [PubMed: 11698199 ].
  31. Vipond et al., 2006: Vipond J, Clark SO, Hatch GJ, Vipond R, Marie Agger E, Tree JA, Williams A, Marsh PD. Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh, Scotland). 2006 May-Jul; 86(3-4); 218-24. [PubMed: 16520093].
  32. Vordermeier et al., 2004: Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, Hewinson RG, Gilbert SC. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology. 2004 Jul; 112(3); 461-70. [PubMed: 15196215].

Mycoplasma gallisepticum

  1. Barbour et al., 2000: Barbour EK, Hamadeh SK, Eidt A. Infection and immunity in broiler chicken breeders vaccinated with a temperature-sensitive mutant of Mycoplasma gallisepticum and impact on performance of offspring. Poultry science. 2000; 79(12); 1730-1735. [PubMed: 11194034].

Mycoplasma synoviae

  1. Morrow et al., 1998: Morrow CJ, Markham JF, Whithear KG. Production of temperature-sensitive clones of Mycoplasma synoviae for evaluation as live vaccines. Avian diseases. 1998; 42(4); 667-670. [PubMed: 9876833].

Neisseria meningitidis

  1. Comanducci et al., 2002: Comanducci M, Bambini S, Brunelli B, Adu-Bobie J, Aricò B, Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, Granoff DM, Caugant DA, Pizza M, Rappuoli R, Mora M. NadA, a novel vaccine candidate of Neisseria meningitidis. The Journal of experimental medicine. 2002; 195(11); 1445-1454. [PubMed: 12045242].
  2. FDA: Menactra: FDA: Menactra [http://www.fda.gov/cber/label/menactraLB.pdf]
  3. FDA: Menomune– A/C/Y/W-135: FDA Menomune– A/C/Y/W-135 Neisseria meningitidis vaccine [http://www.fda.gov/cber/label/menomuneLB.pdf]
  4. Giuliani et al., 2006: Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. A universal vaccine for serogroup B meningococcus. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(29); 10834-10839. [PubMed: 16825336].
  5. Martin et al., 1997: Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. The Journal of experimental medicine. 1997; 185(7); 1173-1183. [PubMed: 9104804].
  6. Pizza et al., 2000: Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, Galeotti CL, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Scarselli M, Storni E, Zuo P, Broeker M, Hundt E, Knapp B, Blair E, Mason T, Tettelin H, Hood DW, Jeffries AC, Saunders NJ, Granoff DM, Venter JC, Moxon ER, Grandi G, Rappuoli R. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (New York, N.Y.). 2000; 287(5459); 1816-1820. [PubMed: 10710308].
  7. Pizza et al., 2008: Pizza M, Donnelly J, Rappuoli R. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine. 2008; 26 Suppl 8; I46-48. [PubMed: 19388164].
  8. Stephens et al., 2007: Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007; 369(9580); 2196-2210. [PubMed: 17604802].

Neospora caninum

  1. Romero et al., 2004: Romero JJ, Pérez E, Frankena K. Effect of a killed whole Neospora caninum tachyzoite vaccine on the crude abortion rate of Costa Rican dairy cows under field conditions. Veterinary parasitology. 2004; 123(3-4); 149-159. [PubMed: 15325041].

Newcastle disease virus

  1. Meeusen et al., 2007: Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clinical microbiology reviews. 2007; 20(3); 489-510. [PubMed: 17630337].

Plasmodium spp.

  1. Adams et al., 2002: Adams S, Brown H, Turner G. Breaking down the blood-brain barrier: signaling a path to cerebral malaria?. Trends in parasitology. 2002 Aug; 18(8); 360-6. [PubMed: 12377286].
  2. Aidoo et al., 2000: Aidoo M, Lalvani A, Gilbert SC, Hu JT, Daubersies P, Hurt N, Whittle HC, Druihle P, Hill AV. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infection and immunity. 2000 Jan; 68(1); 227-32. [PubMed: 10603392].
  3. Alonso et al., 2004: Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004 Oct 16-22; 364(9443); 1411-20. [PubMed: 15488216].
  4. Arevalo-Herrera et al., 2005: Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. The American journal of tropical medicine and hygiene. 2005 Nov; 73(5 Suppl); 32-7. [PubMed: 16291764].
  5. Audran et al., 2005: Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infection and immunity. 2005 Dec; 73(12); 8017-26. [PubMed: 16299295].
  6. BenMohamed et al., 2004: BenMohamed L, Thomas A, Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infection and immunity. 2004 Aug; 72(8); 4376-84. [PubMed: 15271893].
  7. Bledsoe, 2005: Bledsoe GH. Malaria primer for clinicians in the United States. Southern medical journal. 2005 Dec; 98(12); 1197-204; quiz 1205, 1230. [PubMed: 16440920].
  8. Bojang et al., 2001: Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001 Dec 8; 358(9297); 1927-34. [PubMed: 11747915].
  9. Breman, 2001: Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. The American journal of tropical medicine and hygiene. 2001 Jan-Feb; 64(1-2 Suppl); 1-11. [PubMed: 11425172].
  10. Bruna-Romero et al., 2004: Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine. 2004 Sep 9; 22(27-28); 3575-84. [PubMed: 15315836].
  11. Burgess et al., 2005: Burgess BR, Schuck P, Garboczi DN. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. The Journal of biological chemistry. 2005 Nov 4; 280(44); 37236-45. [PubMed: 16135515].
  12. Carter et al., 1995: Carter R, Coulson A, Bhatti S, Taylor BJ, Elliott JF. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Molecular and biochemical parasitology. 1995 May; 71(2); 203-10. [PubMed: 7477102].
  13. Castellanos et al., 2007: Castellanos A, Arevalo-Herrera M, Restrepo N, Gulloso L, Corradin G, Herrera S. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Memorias do Instituto Oswaldo Cruz. 2007 Jun; 102(3); 411-6. [PubMed: 17568948].
  14. Chen et al., 2000: Chen Q, Schlichtherle M, Wahlgren M. Molecular aspects of severe malaria. Clinical microbiology reviews. 2000 Jul; 13(3); 439-50. [PubMed: 10885986].
  15. Dunachie et al., 2006: Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infection and immunity. 2006; 74(10); 5933-5942. [PubMed: 16988273].
  16. Eksi et al., 2006: Eksi S, Czesny B, van Gemert GJ, Sauerwein RW, Eling W, Williamson KC. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Molecular microbiology. 2006 Aug; 61(4); 991-8. [PubMed: 16879650].
  17. Escalante et al., 1998: Escalante AA, Freeland DE, Collins WE, Lal AA. The evolution of primate malaria parasites based on the gene encoding cytochrome b from the linear mitochondrial genome. Proceedings of the National Academy of Sciences of the United States of America. 1998 Jul 7; 95(14); 8124-9. [PubMed: 9653151].
  18. Fanning et al., 2003: Fanning SL, Czesny B, Sedegah M, Carucci DJ, van Gemert GJ, Eling W, Williamson KC. A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230. Vaccine. 2003 Jul 4; 21(23); 3228-35. [PubMed: 12804852].
  19. Flanagan et al., 2003: Flanagan KL, Mwangi T, Plebanski M, Odhiambo K, Ross A, Sheu E, Kortok M, Lowe B, Marsh K, Hill AV. Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. The American journal of tropical medicine and hygiene. 2003 Apr; 68(4); 421-30. [PubMed: 12875291].
  20. Flanagan et al., 2006: Flanagan KL, Plebanski M, Odhiambo K, Sheu E, Mwangi T, Gelder C, Hart K, Kortok M, Lowe B, Robson KJ, Marsh K, Hill AV. Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. The American journal of tropical medicine and hygiene. 2006 Mar; 74(3); 367-75. [PubMed: 16525093].
  21. Gantt et al., 2000: Gantt S, Persson C, Rose K, Birkett AJ, Abagyan R, Nussenzweig V. Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo. Infection and immunity. 2000 Jun; 68(6); 3667-73. [PubMed: 10816526].
  22. Garcia et al., 2006: Garcia JE, Puentes A, Patarroyo ME. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design. Clinical microbiology reviews. 2006 Oct; 19(4); 686-707. [PubMed: 17041140].
  23. Genton et al., 2003: Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. 2003 Dec 8; 22(1); 30-41. [PubMed: 14604568].
  24. Genton et al., 2003a: Genton B, Anders RF, Alpers MP, Reeder JC. The malaria vaccine development program in Papua New Guinea. Trends in parasitology. 2003 Jun; 19(6); 264-70. [PubMed: 12798084].
  25. Gilbert et al., 2006: Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine. 2006 May 22; 24(21); 4554-61. [PubMed: 16150517].
  26. Girard et al., 2007: Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine. 2007 Feb 19; 25(9); 1567-80. [PubMed: 17045367].
  27. Greenwood et al., 2005: Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet. 2005 Apr 23-29; 365(9469); 1487-98. [PubMed: 15850634].
  28. Hay et al., 2004: Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. The Lancet infectious diseases. 2004 Jun; 4(6); 327-36. [PubMed: 15172341].
  29. Heal et al., 1999: Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine. 1999 Sep; 18(3-4); 251-8. [PubMed: 10506649].
  30. Healer et al., 1997: Healer J, McGuinness D, Hopcroft P, Haley S, Carter R, Riley E. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infection and immunity. 1997 Aug; 65(8); 3017-23. [PubMed: 9234748].
  31. Heppner et al., 2005: Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005 Mar 18; 23(17-18); 2243-50. [PubMed: 15755604].
  32. Hillier et al., 2005: Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, Heppner DG, Lanar DE. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infection and immunity. 2005 Apr; 73(4); 2109-15. [PubMed: 15784552].
  33. Joy et al., 2003: Joy DA, Feng X, Mu J, Furuya T, Chotivanich K, Krettli AU, Ho M, Wang A, White NJ, Suh E, Beerli P, Su XZ. Early origin and recent expansion of Plasmodium falciparum. Science (New York, N.Y.). 2003 Apr 11; 300(5617); 318-21. [PubMed: 12690197].
  34. Kaufman et al., 2005: Kaufman TS, Ruveda EA. The quest for quinine: those who won the battles and those who won the war. Angewandte Chemie (International ed. in English). 2005 Jan 28; 44(6); 854-85. [PubMed: 15669029].
  35. Kester et al., 2007: Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine. 2007 Jul 20; 25(29); 5359-66. [PubMed: 17574311].
  36. Kocken et al., 2002: Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, Blackman MJ, Thomas AW. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infection and immunity. 2002 Aug; 70(8); 4471-6. [PubMed: 12117958].
  37. Komisar, 2007: Komisar JL. Malaria vaccines. Frontiers in bioscience : a journal and virtual library. 2007 May 1; 12; 3928-55. [PubMed: 17485348].
  38. Kristoff, 2007: Kristoff J. Malaria stage-specific vaccine candidates. Current pharmaceutical design. 2007; 13(19); 1989-99. [PubMed: 17627532].
  39. Kushwaha et al., 2001: Kushwaha A, Rao PP, Suresh RP, Chauhan VS. Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite immunology. 2001 Aug; 23(8); 435-44. [PubMed: 11489167].
  40. Kwiatkowski et al., 1997: Kwiatkowski D, Marsh K. Development of a malaria vaccine. Lancet. 1997 Dec 6; 350(9092); 1696-701. [PubMed: 9400530].
  41. Kwon et al., 2005: Kwon YU, Soucy RL, Snyder DA, Seeberger PH. Assembly of a series of malarial glycosylphosphatidylinositol anchor oligosaccharides. Chemistry (Weinheim an der Bergstrasse, Germany). 2005 Apr 8; 11(8); 2493-504. [PubMed: 15729674].
  42. Lal et al., 1996: Lal AA, Hughes MA, Oliveira DA, Nelson C, Bloland PB, Oloo AJ, Hawley WE, Hightower AW, Nahlen BL, Udhayakumar V. Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Infection and immunity. 1996 Mar; 64(3); 1054-9. [PubMed: 8641760].
  43. Langermans et al., 2006: Langermans JA, Hensmann M, van Gijlswiik M, Zhang D, Pan W, Giersing BK, Locke E, Dubovsk F, Wittes J, Thomas AW. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques. Human vaccines. 2006 Sep-Oct; 2(5); 222-6. [PubMed: 17035731].
  44. Meis et al., 1983: Meis JF, Verhave JP, Jap PH, Sinden RE, Meuwissen JH. Malaria parasites--discovery of the early liver form. Nature. 1983 Mar 31-Apr 6; 302(5907); 424-6. [PubMed: 6339945].
  45. Moore et al., 2004: Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunological reviews. 2004 Jun; 199; 126-43. [PubMed: 15233731].
  46. Moore et al., 2005: Moore AC, Gallimore A, Draper SJ, Watkins KR, Gilbert SC, Hill AV. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. Journal of immunology (Baltimore, Md. : 1950). 2005 Dec 1; 175(11); 7264-73. [PubMed: 16301631].
  47. Moormann et al., 2006: Moormann AM, John CC, Sumba PO, Tisch D, Embury P, Kazura JW. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area. The American journal of tropical medicine and hygiene. 2006 Apr; 74(4); 585-90. [PubMed: 16606988].
  48. Morais et al., 2006: Morais CG, Soares IS, Carvalho LH, Fontes CJ, Krettli AU, Braga EM. Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity. The American journal of tropical medicine and hygiene. 2006 Oct; 75(4); 582-7. [PubMed: 17038677].
  49. Ong'echa et al., 2003: Ong'echa JM, Lal AA, Terlouw DJ, Ter Kuile FO, Kariuki SK, Udhayakumar V, Orago AS, Hightower AW, Nahlen BL, Shi YP. Association of interferon-gamma responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Asembo Bay Cohort Project. The American journal of tropical medicine and hygiene. 2003 May; 68(5); 590-7. [PubMed: 12812352].
  50. Pearce et al., 2004: Pearce JA, Hodder AN, Anders RF. The alanine-rich heptad repeats are intact in the processed form of Plasmodium falciparum MSP3. Experimental parasitology. 2004 Nov-Dec; 108(3-4); 186-9. [PubMed: 15582517].
  51. PF11_0344 in GeneDB: PF11_0344 in GeneDB [http://www.genedb.org/genedb/Dispatcher?formType=navBar&organism=malaria&desc=yes&wildcard=yes&name=PF11_0344&ohmr=.&ohmr2=.]
  52. PF13_0201 in GeneDB: PF13_0201 in GeneDB [http://www.genedb.org/genedb/Search?organism=malaria&name=PF13_0201&isid=true]
  53. PFL1385c in GeneDB: PFL1385c in GeneDB [http://www.genedb.org/genedb/Search?organism=malaria&name=PFL1385c&isid=true]
  54. Pichyangkul et al., 2004: Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P, Ruble DL, Heppner DG Jr, Kester KE, Ballou WR, Diggs CL, Voss G, Cohen JD, Walsh DS. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine. 2004 Sep 28; 22(29-30); 3831-40. [PubMed: 15364429].
  55. Polhemus et al., 2007: Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 2007 May 22; 25(21); 4203-12. [PubMed: 17442466].
  56. Robson et al., 1998: Robson KJ, Dolo A, Hackford IR, Doumbo O, Richards MB, Keita MM, Sidibe T, Bosman A, Modiano D, Crisanti A. Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. The American journal of tropical medicine and hygiene. 1998 Jan; 58(1); 81-9. [PubMed: 9452297].
  57. Rosa et al., 2004: Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunology letters. 2004 Apr 15; 92(3); 259-68. [PubMed: 15081621].
  58. Schneider et al., 1998: Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature medicine. 1998; 4(4); 397-402. [PubMed: 9546783].
  59. Seeberger et al., 2004: Seeberger PH, Soucy RL, Kwon YU, Snyder DA, Kanemitsu T. A convergent, versatile route to two synthetic conjugate anti-toxin malaria vaccines. Chemical communications (Cambridge, England). 2004 Aug 7; (15); 1706-7. [PubMed: 15278147].
  60. Singh et al., 2003: Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infection and immunity. 2003 Dec; 71(12); 6766-74. [PubMed: 14638762].
  61. Sirima et al., 2007: Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine. 2007 Mar 30; 25(14); 2723-32. [PubMed: 17280744].
  62. Stewart et al., 2007: Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infection and immunity. 2007 May; 75(5); 2283-90. [PubMed: 17307942].
  63. Stoute et al., 2006: Stoute JA, Heppner DG Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. The American journal of tropical medicine and hygiene. 2006 Jul; 75(1); 166-70. [PubMed: 16837726].
  64. Stowers et al., 2002: Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America. 2002 Jan 8; 99(1); 339-44. [PubMed: 11752405].
  65. Sturm et al., 2006: Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennenberg A, Krueger A, Pollok JM, Menard R, Heussler VT. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science (New York, N.Y.). 2006 Sep 1; 313(5791); 1287-90. [PubMed: 16888102].
  66. Talman et al., 2004: Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V. Gametocytogenesis: the puberty of Plasmodium falciparum. Malaria journal. 2004 Jul 14; 3; 24. [PubMed: 15253774].
  67. Thera et al., 2006: Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV. Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase I randomized trial. PLoS clinical trials. 2006 Nov 24; 1(7); e34. [PubMed: 17124530].
  68. Vincent et al., 1999: Vincent AA, Fanning S, Caira FC, Williamson KC. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid. Parasite immunology. 1999 Nov; 21(11); 573-81. [PubMed: 10583858].
  69. Yuen et al., 2007: Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development. Vaccine. 2007 Jan 5; 25(3); 490-9. [PubMed: 16949181].
  70. Zhou et al., 2006: Zhou Z, Todd CW, Wohlhueter RM, Price A, Xiao L, Schnake P, Bonner PC, Martin AM, Goldman IF, De La Vega P, Udhayakumar V, Lal AA. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Human vaccines. 2006 Jan-Feb; 2(1); 14-23. [PubMed: 17012909].

Poliovirus

  1. FDA: IPOL: FDA: IPOL vaccine information [http://www.fda.gov/Cber/products/ipol.htm]
  2. FDA: licensed vaccines: FDA: licensed vaccines [http://www.fda.gov/Cber/vaccine/licvacc.htm]
  3. Poliovax: Medicinenet.com: Poliovax [http://www.medicinenet.com/poliovirus_vaccine-injection/article.htm]
  4. SP: IPV: SP: Inactived Poliomyelitis Vaccine – IPV [https://www.vaccineshoppecanada.com/secure/pdfs/ca/ipv_E.pdf]
  5. Wiki: Poliovirus: Wiki: Poliovirus [http://en.wikipedia.org/wiki/Poliovirus]

Porcine circovirus 2

  1. Ferrari et al., 2000: Ferrari M, Brack A, Romanelli MG, Mettenleiter TC, Corradi A, Dal Mas N, Losio MN, Silini R, Pinoni C, Pratelli A. A study of the ability of a TK-negative and gI/gE-negative pseudorabies virus (PRV) mutant inoculated by different routes to protect pigs against PRV infection. Journal of veterinary medicine. B, Infectious diseases and veterinary public health. 2000; 47(10); 753-762. [PubMed: 11204130].
  2. Wang et al., 2007: Wang X, Jiang P, Li Y, Jiang W, Dong X. Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. Veterinary microbiology. 2007; 121(3-4); 215-224. [PubMed: 17215092].

Pseudorabies virus

  1. Ferrari et al., 2000: Ferrari M, Brack A, Romanelli MG, Mettenleiter TC, Corradi A, Dal Mas N, Losio MN, Silini R, Pinoni C, Pratelli A. A study of the ability of a TK-negative and gI/gE-negative pseudorabies virus (PRV) mutant inoculated by different routes to protect pigs against PRV infection. Journal of veterinary medicine. B, Infectious diseases and veterinary public health. 2000; 47(10); 753-762. [PubMed: 11204130].

Rabies virus

  1. Brochier et al., 1991: Brochier B, Kieny MP, Costy F, Coppens P, Bauduin B, Lecocq JP, Languet B, Chappuis G, Desmettre P, Afiademanyo K. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature. 1991; 354(6354); 520-522. [PubMed: 1758494].
  2. FDA: Imovax: FDA: Imovax vaccine information [http://www.fda.gov/Cber/products/imovax.htm]
  3. FDA: Rabavert: FDA: Rabavert vaccine information [http://www.fda.gov/Cber/products/rabavert.htm]
  4. Mackowiak et al., 1999: Mackowiak M, Maki J, Motes-Kreimeyer L, Harbin T, Van Kampen K. Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Advances in veterinary medicine. 1999; 41; 571-583. [PubMed: 9890044].
  5. Manning et al., 2008: Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2008; 57(RR-3); 1-28. [PubMed: 18496505].
  6. Rabavert: Rabavert Package Insert [http://poisonevercure.150m.com/vaccines/package_inserts/rabavert.pdf]
  7. Rupprecht et al., 2004: Rupprecht CE, Hanlon CA, Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Developments in biologicals. 2004; 119; 173-184. [PubMed: 15742629].
  8. Stoffregen et al., 2006: Stoffregen WC, Olsen SC, Bricker BJ. Parenteral vaccination of domestic pigs with Brucella abortus strain RB51. American journal of veterinary research. 2006; 67(10); 1802-1808. [PubMed: 17014337].
  9. Wiki: Rabies: Wiki: Rabies [http://en.wikipedia.org/wiki/Rabies]

Rotavirus

  1. FDA: ROTARIX: FDA: ROTARIX vaccine information [http://www.fda.gov/Cber/label/rotarixLB.pdf]
  2. FDA: RotaTeq: FDA: RotaTeq vaccine information [http://www.fda.gov/Cber/label/rotateqlb.pdf]
  3. Wiki: Rotavirus: Wiki: Rotavirus [http://en.wikipedia.org/wiki/Rotavirus]

Rubella virus

  1. FDA: Meruvax II: FDA: Meruvax II vaccine information [http://www.fda.gov/Cber/label/rvvmer013107LB.pdf]
  2. FDA: MMR-II: FDA: MMR-II Vaccine [http://www.fda.gov/cber/label/mmriiLB.pdf]
  3. FDA: Proquad: FDA: Proquad Vaccine [http://www.fda.gov/cber/label/proquadLB.pdf]
  4. Wiki: Rebella: Wiki: Rebella [http://en.wikipedia.org/wiki/Rubella]

Salmonella spp.

  1. Babu et al., 2004: Babu U, Dalloul RA, Okamura M, Lillehoj HS, Xie H, Raybourne RB, Gaines D, Heckert RA. Salmonella enteritidis clearance and immune responses in chickens following Salmonella vaccination and challenge. Veterinary immunology and immunopathology. 2004; 101(3-4); 251-257. [PubMed: 15350755].
  2. Boyle et al., 2007: Boyle EC, Bishop JL, Grassl GA, Finlay BB. Salmonella: from pathogenesis to therapeutics. Journal of bacteriology. 2007; 189(5); 1489-1495. [PubMed: 17189373].
  3. Burns et al: Megan Egg – protection for commercial layers against Salmonella enteritidis infection for consumer protection [http://www.fda.gov/ohrms/dockets/dockets/00n0504/00N-0504_emc-001650-02.pdf]
  4. Cárdenas and Clements, 1992: Cárdenas L, Clements JD. Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clinical microbiology reviews. 1992; 5(3); 328-342. [PubMed: 1498769].
  5. Cheminay and Hensel, 2007: Cheminay C, Hensel M. Rational design of Salmonella recombinant vaccines. International journal of medical microbiology : IJMM. 2007; ; . [PubMed: 17888730 ].
  6. FDA: Vivotif: FDA: Vivotif Vaccine for Salmonella [http://www.fda.gov/cber/label/VivotiLB.pdf]
  7. Frech et al., 1998: Frech G, Weide-Botjes M, Nussbeck E, Rabsch W, Schwarz S. Molecular characterization of Salmonella enterica subsp. enterica serovar Typhimurium DT009 isolates: differentiation of the live vaccine strain Zoosaloral from field isolates. FEMS microbiology letters. 1998; 167(2); 263-269. [PubMed: 9809427].
  8. Game Bird Health - Broilact: Game Bird Health - Broilact [http://www.gamebirdhealth.co.uk/broilact.htm]
  9. Levine et al., 2007: Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007; 45 Suppl 1; S24-28. [PubMed: 17582564].
  10. Methner et al., 1997: Methner U, Barrow PA, Martin G, Meyer H. Comparative study of the protective effect against Salmonella colonisation in newly hatched SPF chickens using live, attenuated Salmonella vaccine strains, wild-type Salmonella strains or a competitive exclusion product. International journal of food microbiology. 1997; 35(3); 223-230. [PubMed: 9105931].
  11. Pasetti et al., 1999: Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clinical immunology (Orlando, Fla.). 1999; 92(1); 76-89. [PubMed: 10413655].
  12. Salvat et al., 1992: Salvat G, Lalande F, Humbert F, Lahellec C. Use of a competitive exclusion product (Broilact) to prevent Salmonella colonization of newly hatched chicks. International journal of food microbiology. 1992; 15(3-4); 307-311. [PubMed: 1419536 ].
  13. Schneitz and Renney, 2003: Schneitz C, Renney DJ. Effect of a commerical competitive exclusion product on the colonization of Salmonella infantis in day-old pheasant chicks. Avian diseases. 2003; 47(4); 1448-1451. [PubMed: 14708995 ].
  14. Tacket and Levine, 2007: Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007; 45 Suppl 1; S20-23. [PubMed: 17582563].
  15. Tacket et al., 2000: Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP, Edelman R, Perry J, Bedford P, Brown D, Chatfield S, Dougan G, Levine MM. Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infection and immunity. 2000; 68(3); 1196-1201. [PubMed: 10678926].
  16. Typhim Vi: FDA: Typhim Vi Vaccine for Salmonella [http://www.fda.gov/cber/label/typhimviLB.pdf]
  17. Wang et al., 2000: Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infection and immunity. 2000; 68(8); 4647-4652. [PubMed: 10899868].

Sarcocystis neurona

  1. Marsh et al., 2004: Marsh AE, Lakritz J, Johnson PJ, Miller MA, Chiang YW, Chu HJ. Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine. Veterinary therapeutics : research in applied veterinary medicine. 2004; 5(1); 34-42. [PubMed: 15150728].

Shigella

  1. Altboum et al., 2001: Altboum Z, Barry EM, Losonsky G, Galen JE, Levine MM. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infection and immunity. 2001; 69(5); 3150-3158. [PubMed: 11292735].
  2. Chakrabarti et al., 1999: Chakrabarti MK, Bhattacharya J, Bhattacharya MK, Nair GB, Bhattacharya SK, Mahalanabis D. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta paediatrica (Oslo, Norway : 1992). 1999; 88(2); 161-165. [PubMed: 10102148].
  3. Coster et al., 1999: Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infection and immunity. 1999; 67(7); 3437-3443. [PubMed: 10377124].
  4. Hartman and Venkatesan, 1998: Hartman AB, Venkatesan MM. Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infection and immunity. 1998; 66(9); 4572-4576. [PubMed: 9712824].
  5. Hartman et al., 1991: Hartman AB, Powell CJ, Schultz CL, Oaks EV, Eckels KH. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infection and immunity. 1991; 59(11); 4075-4083. [PubMed: 1937767].
  6. Klee et al., 1997: Klee SR, Tzschaschel BD, Fält I, Kärnell A, Lindberg AA, Timmis KN, Guzmán CA. Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1. Infection and immunity. 1997; 65(6); 2112-2118. [PubMed: 9169740].
  7. Kotloff et al., 1992: Kotloff KL, Herrington DA, Hale TL, Newland JW, Van De Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infection and immunity. 1992; 60(6); 2218-2224. [PubMed: 1587589].
  8. Kotloff et al., 2000: Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infection and immunity. 2000; 68(3); 1034-1039. [PubMed: 10678904].
  9. Kotloff et al., 2002: Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infection and immunity. 2002; 70(4); 2016-2021. [PubMed: 11895966].
  10. Kotloff et al., 2004: Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD, Levine MM. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. The Journal of infectious diseases. 2004; 190(10); 1745-1754. [PubMed: 15499528].
  11. Kotloff et al., 2007: Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, Nataro JP, Blackwelder WC, Barry EM, Picking W, Levine MM. Safety and Immunogenicity of CVD 1208S, a Live, Oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a Vaccine Grown on Animal-Free Media. Human vaccines. 2007; 3(6); . [PubMed: 17938573 ].
  12. Niyogi, 2005: Niyogi SK. Shigellosis. Journal of microbiology (Seoul, Korea). 2005; 43(2); 133-143. [PubMed: 15880088].
  13. Noriega et al., 1994: Noriega FR, Wang JY, Losonsky G, Maneval DR, Hone DM, Levine MM. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infection and immunity. 1994; 62(11); 5168-5172. [PubMed: 7927802].
  14. Noriega et al., 1996: Noriega FR, Losonsky G, Lauderbaugh C, Liao FM, Wang JY, Levine MM. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infection and immunity. 1996; 64(8); 3055-3061. [PubMed: 8757833].
  15. Orr et al., 1993: Orr N, Robin G, Cohen D, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infection and immunity. 1993; 61(6); 2390-2395. [PubMed: 8500877].
  16. Osorio et al., 2007: Osorio M, Bray MD, Walker RI. Vaccine potential for inactivated shigellae. Vaccine. 2007; 25(9); 1581-1592. [PubMed: 17178431].
  17. Schneider et al., 1998: Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature medicine. 1998; 4(4); 397-402. [PubMed: 9546783].
  18. Shim et al., 2007: Shim DH, Chang SY, Park SM, Jang H, Carbis R, Czerkinsky C, Uematsu S, Akira S, Kweon MN. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a. Vaccine. 2007; 25(25); 4828-4836. [PubMed: 17507120].
  19. Venkatesan et al., 2002: Venkatesan MM, Hartman AB, Newland JW, Ivanova VS, Hale TL, McDonough M, Butterton J. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infection and immunity. 2002; 70(6); 2950-2958. [PubMed: 12010984].

Streptococcus equi

  1. Jacobs et al., 2000: Jacobs AA, Goovaerts D, Nuijten PJ, Theelen RP, Hartford OM, Foster TJ. Investigations towards an efficacious and safe strangles vaccine: submucosal vaccination with a live attenuated Streptococcus equi. The Veterinary record. 2000; 147(20); 563-567. [PubMed: 11104039].

Streptococcus pneumoniae

  1. FDA: PNEUMOVAX 23: FDA: PNEUMOVAX 23 Vaccine for Streptococcus pneumoniae [http://www.fda.gov/cber/label/pneumovax23lb.pdf]
  2. FDA: Prevnar: FDA: Pneumococcal 7-valent Conjugate Vaccine [http://www.fda.gov/Cber/label/prevnarLB.pdf]
  3. Merck: PNEUMOVAX 23: Merck: PNEUMOVAX 23 [http://www.merckvaccines.com/vaccines/pneu/index.html]
  4. Ortqvist et al., 2005: Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Seminars in respiratory and critical care medicine. 2005; 26(6); 563-574. [PubMed: 16388428].
  5. Wiki: S. pneumoniae: Wikipedia: Streptococcus pneumoniae [http://en.wikipedia.org/wiki/Streptococcus_pneumoniae]

Theileria annulata

  1. Shkap and Pipano, 2000: Shkap V, Pipano E. Culture-derived parasites in vaccination of cattle against tick-borne diseases. Annals of the New York Academy of Sciences. 2000; 916; 154-171. [PubMed: 11193616].

Theileria parva

  1. Boulter and Hall, 1999: Boulter N, Hall R. Immunity and vaccine development in the bovine theilerioses. Advances in parasitology. 1999; 44; 41-97. [PubMed: 10563395].

Toxoplasma gondii

  1. Buxton and Innes, 1995: Buxton D, Innes EA. A commercial vaccine for ovine toxoplasmosis. Parasitology. 1995; 110 Suppl; S11-16. [PubMed: 7784124].

Varicella-zoster virus

  1. FDA: ProQuad: FDA: ProQuad Vaccine [http://www.fda.gov/cber/label/proquadLB.pdf]
  2. FDA: VARIVAX: FDA: VARIVAX vaccine information [http://www.fda.gov/Cber/label/varmer110906lb1.pdf]
  3. FDA: Zostavax: FDA: Zostavax vaccine information [http://www.fda.gov/Cber/label/zostavaxLB.pdf]
  4. GSK: Varilrix: GSK: Varilrix Product Information [http://www.gsk.ca/english/docs-pdf/varilrix_PM_20070110.pdf]
  5. Wiki: Varicella zoster: Wiki: Varicella zoster [http://en.wikipedia.org/wiki/Varicella_zoster]

Variola virus

  1. Amanna et al., 2006: Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunological reviews. 2006 Jun; 211; 320-37. [PubMed: 16824139 ].
  2. Belyakov et al., 2003: Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proceedings of the National Academy of Sciences of the United States of America. 2003 Aug 5; 100(16); 9458-63. [PubMed: 12869693 ].
  3. Berhanu et al., 2008: Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. Journal of virology. 2008; 82(7); 3517-3529. [PubMed: 18199639].
  4. Bielinska et al., 2008: Bielinska AU, Chepurnov AA, Landers JJ, Janczak KW, Chepurnova TS, Luker GD, Baker JR Jr. A novel, killed-virus nasal vaccinia virus vaccine. Clinical and vaccine immunology : CVI. 2008; 15(2); 348-358. [PubMed: 18057181].
  5. Casey et al., 2005: Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Torok TJ, Chapman LE, Swerdlow DL, Morgan J, Heffelfinger JD, Vitek C, Reef SE, Hasbrouck LM, Damon I, Neff L, Vellozzi C, McCauley M, Strikas RA, Mootrey G. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA : the journal of the American Medical Association. 2005 Dec 7; 294(21); 2734-43. [PubMed: 16333009 ].
  6. Earl et al., 2004: Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004 Mar 11; 428(6979); 182-5. [PubMed: 15014500].
  7. Edghill-Smith et al., 2003: Edghill-Smith Y, Venzon D. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. The Journal of infectious diseases. 2003 Oct 15; 188(8); 1181-91. [PubMed: 14551889 ].
  8. Empig et al., 2006: Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine. 2006 Apr 24; 24(17); 3686-94. [PubMed: 16430997 ].
  9. FDA: ACAM2000: FDA: ACAM2000 Vaccine for Variola Virus [http://www.fda.gov/cber/label/acam2000LB.pdf]
  10. FDA: Dryvax: FDA: Dryvax Vaccine for Variola Virus [http://www.fda.gov/cber/label/dryvaxLB.pdf]
  11. Fogg et al., 2004: Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. Journal of virology. 2004 Oct; 78(19); 10230-7. [PubMed: 15367588 ].
  12. Franz et al., 1997: Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr. Clinical recognition and management of patients exposed to biological warfare agents. JAMA : the journal of the American Medical Association. 1997 Aug 6; 278(5); 399-411. [PubMed: 9244332].
  13. Grabenstein et al., 2003: Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA : the journal of the American Medical Association. 2003 Jun 25; 289(24); 3278-82. [PubMed: 12824209 ].
  14. Greenberg et al., 2005: Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, Cruz J, Ennis FA, Blackwelder WC, Hopkins RJ. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet. 2005 Jan 29-Feb 4; 365(9457); 398-409. [PubMed: 15680454 ].
  15. Hassett, 2003: Hassett DE. Smallpox infections during pregnancy, lessons on pathogenesis from nonpregnant animal models of infection. Journal of reproductive immunology. 2003 Oct; 60(1); 13-24. [PubMed: 14568674].
  16. Henderson, 1999: Henderson DA. Smallpox: clinical and epidemiologic features. Emerging infectious diseases. 1999 Jul-Aug; 5(4); 537-9. [PubMed: 10458961].
  17. Hooper et al., 2004: Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ichou MA, Steffen SE, Schmaljohn CS, Schmaljohn AL, Jahrling PB. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. Journal of virology. 2004 May; 78(9); 4433-43. [PubMed: 15078924].
  18. Hooper et al., 2006: Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine. 2006 Nov 27; ; . [PubMed: 17240007].
  19. McFadden, 2005: McFadden G. Poxvirus tropism. Nature reviews. Microbiology. 2005 Mar; 3(3); 201-13. [PubMed: 15738948].
  20. Meseda et al., 2005: Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology. 2005 Sep 1; 339(2); 164-75. [PubMed: 15993917 ].
  21. Monath et al., 2004: Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, Liu J, Gardner B, Downing G, Blum PS, Kemp T, Nichols R, Weltzin R. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2004 Oct; 8 Suppl 2; S31-44. [PubMed: 15491873].
  22. Morikawa et al., 2005: Morikawa S, Sakiyama T, Hasegawa H, Saijo M, Maeda A, Kurane I, Maeno G, Kimura J, Hirama C, Yoshida T, Asahi-Ozaki Y, Sata T, Kurata T, Kojima A. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. Journal of virology. 2005 Sep; 79(18); 11873-91. [PubMed: 16140764].
  23. NCBI: Entrez Gene [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene]
  24. Ober et al., 2002: Ober BT, Bruhl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. Journal of virology. 2002 Aug; 76(15); 7713-23. [PubMed: 12097585].
  25. Parrino et al., 2006: Parrino J, Graham BS. Smallpox vaccines: Past, present, and future. The Journal of allergy and clinical immunology. 2006 Dec; 118(6); 1320-6. [PubMed: 17157663 ].
  26. PathPort: Virginia Bioinformatics Institute [http://pathport.vbi.vt.edu/pathinfo/pathogens/Clostridium_botulinum_Info.shtml]
  27. Slifka, 2004: Slifka MK. Immunological memory to viral infection. Current opinion in immunology. 2004 Aug; 16(4); 443-50. [PubMed: 15245737].
  28. Stittelaar et al., 2005: Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, Niesters HG, van Doornum G, van der Zeijst BA, Mateo L, Chaplin PJ, Osterhaus AD. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. Journal of virology. 2005 Jun; 79(12); 7845-51. [PubMed: 15919938 ].
  29. Sugimoto et al., 1994: Sugimoto M, Yamanouchi K. Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines. Vaccine. 1994 Jun; 12(8); 675-81. [PubMed: 8091843].
  30. Vilesova et al., 1985: Vilesova IS, Gurvich EB, Dzagurov SG, Grigor'eva LV, Abel H. [Changes in the properties of the vaccinia virus isolated in postvaccinal encephalitis]. Voprosy virusologii. 1985 Jul-Aug; 30(4); 477-82. [PubMed: 2865855].
  31. Vollmar et al., 2006: Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hulsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine. 2006 Mar 15; 24(12); 2065-70. [PubMed: 16337719].
  32. Weltzin et al., 2003: Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, Nichols R, Johnson C, Cruz J, Kennedy JS, Ennis FA, Monath TP. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nature medicine. 2003 Sep; 9(9); 1125-30. [PubMed: 12925845 ].

VEE Virus

  1. Bennett et al., 2000: Bennett AM, Elvin SJ, Wright AJ, Jones SM, Phillpotts RJ. An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine. 2000 Sep 15; 19(2-3); 337-47. [PubMed: 10930689].
  2. Bett et al., 1995: Bett AJ, Krougliak V, Graham FL. DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Virus research. 1995 Nov; 39(1); 75-82. [PubMed: 8607286].
  3. BMDP Statistics Software 1992: . BMDP Statistics Software. 467. BMDP Statistics Software Release 7. 1992. , .
  4. Bray et al., 1999: Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. The Journal of infectious diseases. 1999 Feb; 179 Suppl 1; S248-58. [PubMed: 9988191].
  5. Bredenbeek et al., 1993: Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. Journal of virology. 1993 Nov; 67(11); 6439-46. [PubMed: 8411346 ].
  6. Connolly et al., 1999: Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, Jahrling PB. Pathogenesis of experimental Ebola virus infection in guinea pigs. The Journal of infectious diseases. 1999 Feb; 179 Suppl 1; S203-17. [PubMed: 9988186].
  7. Davis et al., 1989: Davis NL, Willis LV, Smith JF, Johnston RE. In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology. 1989 Jul; 171(1); 189-204. [PubMed: 2525837].
  8. Davis et al., 1991: Davis NL, Powell N, Greenwald GF, Willis LV, Johnson BJ, Smith JF, Johnston RE. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology. 1991 Jul; 183(1); 20-31. [PubMed: 2053280 ].
  9. Davis et al., 1996: Davis NL, Brown KW, Johnston RE. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. Journal of virology. 1996 Jun; 70(6); 3781-7. [PubMed: 8648713].
  10. Eddy et al., 1972: Eddy GA, Martin DH, Reeves WC, Johnson KM. Field studies of an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83). Infection and immunity. 1972 Feb; 5(2); 160-3. [PubMed: 4564397].
  11. Fine et al., 2007: Fine DL, Roberts BA, Teehee ML, Terpening SJ, Kelly CL, Raetz JL, Baker DC, Powers AM, Bowen RA. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine. 2007 Feb 26; 25(10); 1868-76. [PubMed: 17240002].
  12. Grieder et al., 1995: Grieder FB, Davis NL, Aronson JF, Charles PC, Sellon DC, Suzuki K, Johnston RE. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology. 1995 Feb 1; 206(2); 994-1006. [PubMed: 7856110].
  13. Guyton, A.C., 1947: Guyton, A.C.. Measurement of the respiratory volume of laboratory animals. Am. J. Physiol.. 1947; 150; 10-11.
  14. Hart et al., 1997: Hart MK, Pratt W, Panelo F, Tammariello R, Dertzbaugh M. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Vaccine. 1997 Mar; 15(4); 363-9. [PubMed: 9141206 ].
  15. Hevey et al., 1997: Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 1997 Dec 8; 239(1); 206-16. [PubMed: 9426460 ].
  16. Jones et al., 1979: Jones N, Shenk T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell. 1979 Jul; 17(3); 683-9. [PubMed: 476833].
  17. Moe et al., 1981: Moe JB, Lambert RD, Lupton HW. Plaque assay for Ebola virus. Journal of clinical microbiology. 1981 Apr; 13(4); 791-3. [PubMed: 7014628].
  18. Paessler et al., 2003: Paessler S, Fayzulin RZ, Anishchenko M, Greene IP, Weaver SC, Frolov I. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. Journal of virology. 2003 Sep; 77(17); 9278-86. [PubMed: 12915543 ].
  19. Paessler et al., 2006: Paessler S, Ni H, Petrakova O, Fayzulin RZ, Yun N, Anishchenko M, Weaver SC, Frolov I. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. Journal of virology. 2006 Mar; 80(6); 2784-96. [PubMed: 16501087].
  20. Phillpotts et al., 1997: Phillpotts RJ, Brooks TJ, Cox CS. A simple device for the exposure of animals to infectious microorganisms by the airborne route. Epidemiology and infection. 1997 Feb; 118(1); 71-5. [PubMed: 9042037 ].
  21. Phillpotts et al., 1999: Phillpotts RJ, Wright AJ. TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus. Vaccine. 1999 Feb 26; 17(7-8); 982-8. [PubMed: 10067707].
  22. Phillpotts et al., 2002: Phillpotts RJ, Jones LD, Howard SC. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine. 2002 Feb 22; 20(11-12); 1497-504. [PubMed: 11858855 ].
  23. Phillpotts et al., 2005: Phillpotts RJ, O'brien L, Appleton RE, Carr S, Bennett A. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine. 2005 Feb 18; 23(13); 1615-23. [PubMed: 15694514].
  24. Phillpotts, 2006: Phillpotts RJ. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus research. 2006 Sep; 120(1-2); 107-12. [PubMed: 16621103 ].
  25. Pifat et al., 1988: Pifat DY, Osterling MC, Smith JF. Antigenic analysis of Punta Toro virus and identification of protective determinants with monoclonal antibodies. Virology. 1988 Dec; 167(2); 442-50. [PubMed: 2462308 ].
  26. Pratt et al., 1998: Pratt WD, Gibbs P, Pitt ML, Schmaljohn AL. Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates. Vaccine. 1998 May-Jun; 16(9-10); 1056-64. [PubMed: 9682359].
  27. Pratt et al., 2003: Pratt WD, Davis NL, Johnston RE, Smith JF. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine. 2003 Sep 8; 21(25-26); 3854-62. [PubMed: 12922119].
  28. Pushko et al., 1997: Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 1997 Dec 22; 239(2); 389-401. [PubMed: 9434729].
  29. Pushko et al., 2000: Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000 Aug 15; 19(1); 142-53. [PubMed: 10924796].
  30. Sanchez et al., 1989: Sanchez A, Kiley MP, Holloway BP, McCormick JB, Auperin DD. The nucleoprotein gene of Ebola virus: cloning, sequencing, and in vitro expression. Virology. 1989 May; 170(1); 81-91. [PubMed: 2718390].
  31. Sanchez et al., 1993: Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus research. 1993 Sep; 29(3); 215-40. [PubMed: 8237108 ].
  32. Tollefson et al., 2007: Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WS. Preparation and titration of CsCl-banded adenovirus stocks. Methods in molecular medicine. 2007; 130; 223-35. [PubMed: 17401177].
  33. Walton et al., 1972: Walton TE, Alvarez O Jr, Buckwalter RM, Johnson KM. Experimental infection of horses with an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83). Infection and immunity. 1972 May; 5(5); 750-6. [PubMed: 4637604].
  34. Walton et al., 1973: Walton TE, Alvarez O Jr, Buckwalter RM, Johnson KM. Experimental infection of horses with enzootic and epizootic strains of Venezuelan equine encephalomyelitis virus. The Journal of infectious diseases. 1973 Sep; 128(3); 271-82. [PubMed: 4728689 ].
  35. Weaver et al., 2004: Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC. Venezuelan equine encephalitis. Annual review of entomology. 2004; 49; 141-74. [PubMed: 14651460 ].
  36. Wright et al., 1998: Wright AJ, Phillpotts RJ. Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice. Archives of virology. 1998; 143(6); 1155-62. [PubMed: 9687872 ].

West Nile virus

  1. Davis et al., 2001: Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. Journal of virology. 2001; 75(9); 4040-4047. [PubMed: 11287553].
  2. Minke et al., 2004: Minke JM, Audonnet JC, Fischer L. Equine viral vaccines: the past, present and future. Veterinary research. 2004; 35(4); 425-443. [PubMed: 15236675].
  3. Monath et al., 2001: Monath TP, Arroyo J, Miller C, Guirakhoo F. West Nile virus vaccine. Current drug targets. Infectious disorders. 2001; 1(1); 37-50. [PubMed: 12455232].

Yellow fever virus

  1. FDA: YF-Vax: FDA: YF-Vax vaccine information [http://www.fda.gov/Cber/label/yfvaxLB.pdf]
  2. Wiki: Yellow fever: Wiki: Yellow fever [http://en.wikipedia.org/wiki/Yellow_fever]

Yersinia pestis

  1. Alvarez et al., 2006: Alvarez ML, Pinyerd HL, Crisantes JD, Rigano MM, Pinkhasov J, Walmsley AM, Mason HS, Cardineau GA. Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice. Vaccine. 2006; 24(14); 2477-2490. [PubMed: 16442673].
  2. Anderson et al., 1996: Anderson GW Jr, Leary SE, Williamson ED, Titball RW, Welkos SL, Worsham PL, Friedlander AM. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infection and immunity. 1996 Nov; 64(11); 4580-5. [PubMed: 8890210].
  3. Andrews et al., 1996: Andrews GP, Heath DG, Anderson GW Jr, Welkos SL, Friedlander AM. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infection and immunity. 1996 Jun; 64(6); 2180-7. [PubMed: 8675324].
  4. Andrews et al., 1999: Andrews GP, Strachan ST, Benner GE, Sample AK, Anderson GW Jr, Adamovicz JJ, Welkos SL, Pullen JK, Friedlander AM. Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infection and immunity. 1999 Mar; 67(3); 1533-7. [PubMed: 10024607 ].
  5. Bashaw et al., 2007: Bashaw J, Norris S, Weeks S, Trevino S, Adamovicz JJ, Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clinical and vaccine immunology : CVI. 2007 May; 14(5); 605-16. [PubMed: 17376861 ].
  6. Carr et al., 1999: Carr S, Miller J, Leary SE, Bennett AM, Ho A, Williamson ED. Expression of a recombinant form of the V antigen of Yersinia pestis, using three different expression systems. Vaccine. 1999 Aug 20; 18(1-2); 153-9. [PubMed: 10501245].
  7. Chiuchiolo et al., 2006: Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG. Protective Immunity against Respiratory Tract Challenge with Yersinia pestis in Mice Immunized with an Adenovirus-Based Vaccine Vector Expressing V Antigen. The Journal of infectious diseases. 2006 Nov 1; 194(9); 1249-57. [PubMed: 17041851].
  8. Cornelis, 2002: Cornelis GR. Yersinia type III secretion: send in the effectors. The Journal of cell biology. 2002 Aug 5; 158(3); 401-8. [PubMed: 12163464].
  9. DeBord et al., 2006: DeBord KL, Anderson DM, Marketon MM, Overheim KA, DePaolo RW, Ciletti NA, Jabri B, Schneewind O. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. Infection and immunity. 2006 Aug; 74(8); 4910-4. [PubMed: 16861680].
  10. Elvin et al., 2006: Elvin SJ, Eyles JE, Howard KA, Ravichandran E, Somavarappu S, Alpar HO, Williamson ED. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. Vaccine. 2006 May 15; 24(20); 4433-9. [PubMed: 16546306].
  11. Grosfeld et al., 2003: Grosfeld H, Cohen S, Bino T, Flashner Y, Ber R, Mamroud E, Kronman C, Shafferman A, Velan B. Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infection and immunity. 2003 Jan; 71(1); 374-83. [PubMed: 12496187 ].
  12. Heesemann et al., 2006: Heesemann J, Sing A, Trulzsch K. Yersinia's stratagem: targeting innate and adaptive immune defense. Current opinion in microbiology. 2006 Feb; 9(1); 55-61. [PubMed: 16413818 ].
  13. Jones et al., 2000: Jones SM, Day F, Stagg AJ, Williamson ED. Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine. 2000 Sep 15; 19(2-3); 358-66. [PubMed: 10930691].
  14. Jones et al., 2003: Jones SM, Griffin KF, Hodgson I, Williamson ED. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine. 2003 Sep 8; 21(25-26); 3912-8. [PubMed: 12922126].
  15. Leary et al., 1995: Leary SE, Williamson ED, Griffin KF, Russell P, Eley SM, Titball RW. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infection and immunity. 1995 Aug; 63(8); 2854-8. [PubMed: 7622205].
  16. Makoveichuk et al., 2003: Makoveichuk E, Cherepanov P, Lundberg S, Forsberg A, Olivecrona G. pH6 antigen of Yersinia pestis interacts with plasma lipoproteins and cell membranes. Journal of lipid research. 2003 Feb; 44(2); 320-30. [PubMed: 12576514 ].
  17. Matson et al., 2005: Matson JS, Durick KA, Bradley DS, Nilles ML. Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC microbiology. 2005 Jun 24; 5(1); 38. [PubMed: 15978133].
  18. Meyer, 1970: Meyer KF. Effectiveness of live or killed plague vaccines in man. Bulletin of the World Health Organization. 1970; 42(5); 653-66. [PubMed: 4988692].
  19. Montminy et al., 2006: Montminy SW, Khan N, McGrath S, Walkowicz MJ, Sharp F, Conlon JE, Fukase K, Kusumoto S, Sweet C, Miyake K, Akira S, Cotter RJ, Goguen JD, Lien E. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nature immunology. 2006 Oct; 7(10); 1066-73. [PubMed: 16980981 ].
  20. Motin et al., 1994: Motin VL, Nakajima R, Smirnov GB, Brubaker RR. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infection and immunity. 1994 Oct; 62(10); 4192-201. [PubMed: 7927675].
  21. Nakajima et al., 1995: Nakajima R, Motin VL, Brubaker RR. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infection and immunity. 1995 Aug; 63(8); 3021-9. [PubMed: 7622225].
  22. NCBI: Entrez Gene [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene]
  23. Palin et al., 2006: Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine. 2006 Aug 22; ; . [PubMed: 16959385].
  24. Palin et al., 2007: Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine. 2007 Jan 8; 25(4); 741-50. [PubMed: 16959385].
  25. Perry et al., 1997: Perry RD, Fetherston JD. Yersinia pestis--etiologic agent of plague. Clinical microbiology reviews. 1997 Jan; 10(1); 35-66. [PubMed: 8993858].
  26. Price et al., 1989: Price SB, Leung KY, Barve SS, Straley SC. Molecular analysis of lcrGVH, the V antigen operon of Yersinia pestis. Journal of bacteriology. 1989 Oct; 171(10); 5646-53. [PubMed: 2477361].
  27. Robinson et al., 2005: Robinson VL, Oyston PC, Titball RW. A dam mutant of Yersinia pestis is attenuated and induces protection against plague. FEMS microbiology letters. 2005 Nov 15; 252(2); 251-6. [PubMed: 16188402].
  28. Russell et al., 1995: Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ, Titball RW. A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine. 1995 Nov; 13(16); 1551-6. [PubMed: 8578841].
  29. Titball et al., 2001: Titball RW, Williamson ED. Vaccination against bubonic and pneumonic plague. Vaccine. 2001 Jul 20; 19(30); 4175-84. [PubMed: 11457543].
  30. Titball et al., 2004: Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert opinion on biological therapy. 2004 Jun; 4(6); 965-73. [PubMed: 15174978].
  31. Une et al., 1984: Une T, Brubaker RR. Roles of V antigen in promoting virulence and immunity in yersiniae. Journal of immunology (Baltimore, Md. : 1950). 1984 Oct; 133(4); 2226-30. [PubMed: 6381597].
  32. Wang et al., 2004: Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X, Chou TH, Goguen J, Lu S. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine. 2004 Sep 3; 22(25-26); 3348-57. [PubMed: 15308359 ].
  33. Welkos et al., 2002: Welkos S, Pitt ML, Martinez M, Friedlander A, Vogel P, Tammariello R. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine. 2002 May 22; 20(17-18); 2206-14. [PubMed: 12009274].
  34. Williams et al., 1979: Williams JE, Cavanaugh DC. Measuring the efficacy of vaccination in affording protection against plague. Bulletin of the World Health Organization. 1979; 57(2); 309-13. [PubMed: 312163].
  35. Williamson et al., 2000: Williamson ED, Eley SM, Stagg AJ, Green M, Russell P, Titball RW. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine. 2000 Oct 15; 19(4-5); 566-71. [PubMed: 11027822].
  36. Williamson et al., 2002: Williamson ED, Bennett AM, Perkins SD, Beedham RJ, Miller J, Baillie LW. Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine. 2002 Jul 26; 20(23-24); 2933-41. [PubMed: 12126905].
  37. Williamson et al., 2005: Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL, Gwyther RJ, Miller J, Packer PJ, Irving M. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infection and immunity. 2005 Jun; 73(6); 3598-608. [PubMed: 15908389].